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Abstract 
Metabolic remodeling is thought to be an important contributor towards the 
development of various cardiac pathophysiologic conditions. Therefore, studies 
attempting to delineate undenying mechanisms driving cardiac metabolic 
remodeling represent an important initiative toward the development of novel 
therapeutic interventions. To further investigate the role of metabolic substrate 
switches in the heart, we focused on a pivotal, rate-limiting step of cardiac fatty 
acid metabolism i.e. an upstream modulator of long-chain fatty acid importation 
into the mitochondrion. In the heart, long-chain fatty acids are transported into 
the mitochondrion by the rate-limiting enzyme, carnitine palmitoyl transferase 1 
(CPT1). CPT1 is potently inhibited by malonyl-CoA, the product of the acetyl-
CoA carboxylation reaction that is catalyzed by acetyl-CoA carboxylase (ACC). 
Recent studies have demonstrated that metabolic fuels such as fatty acids and 
glucose can function as signaling ligands, directing transcriptional regulation of 
numerous metabolic genes. However, transcriptional mechanisms directing the 
gene expression of the cardiac isoform of acetyl-CoA carboxylase (ACC[3) are 
less well understood. Previously, four E-box (CANNTG) sequence motifs were 
identified on the human ACC[3 promoter. Since E-boxes act as binding sites for 
upstream stimulatory factors (US F), putative glucose-responsive transcriptional 
modulators, we hypothesized that ACC[3 is induced by USF1 in a glucose-
dependent manner. 
To investigate this, we began by acutely fasting and subsequently refeeding 
Balb/C mice with a carbohydrate-enriched diet. Here, high carbohydrate feeding 
resulted in elevated systemic glucose levels associated with increased cardiac 
ACC[3 gene and protein expression. To further explore these interesting findings, 
we tranSiently cotransfected neonatal card iom yocytes , H9C2 myoblasts, CV-1 
fibroblasts and HepG2 hepatocytes with the full-length and deletion constructs of 
the human ACC[3 gene promoter together with a putative activator and repressor 
xi 
expression vector, respectively: a) USF1 (glucose-responsive transcription 
factor) - the rationale that it should elevate ACCI3 gene promoter activity in 
accordance with the glucose-fatty acid cycle, and b) nuclear respiratory factor 1 
(NRF1) - the hypothesis being that this mitochondrial biogenesis and l3-oxidation 
enhancing modulator would be expected to attenuate ACCI3 promoter activity in 
order to increase fatty acid oxidation capacity. 
To assess whether USF1 plays a role in ACCI3 gene induction in response to 
increased glucose supply, we performed cotransfection stUdies together with a 
USF1 expression vector under low or high glucose exposure. We found that 
USF1 overexpression markedly elevates ACCI3 promoter activity in neonatal 
cardiomyocytes and CV-1 'fibroblasts under low glucose culturing conditions. 
Moreover, high glucose levels Significantly increased USF1-mediated ACCI3 
promoter activation compared to the low glucose exposure in CV-1 fibroblasts. 
These data suggest that glucose-responsive USF1 transactivation of the human 
ACCI3 gene promoter occurs in a cell-type specific manner i.e. unlike the CV-1 
fibroblasts the USF1 response in neonatal cardiac myocytes appears to be 
glucose-independent. We next performed transfection assays in the presence of 
2-deoxyglucose, a glucose analog that is taken up into the cell and not further 
metabolized. In agreement with our earlier findings, 2-deoxyglucose did not 
inhibit the USF1-mediated transactivation of the human ACCI3 gene promoter 
activity in neonatal cardiomyocytes. In contrast, 2-deoxyglucose administration 
robustly inhibited USF1-mediated human ACCI3 promoter activity in CV-1 
fibroblasts. We next tested whether phosphatase 2A (PP2A), a downstream 
target of the pentose phosphate metabolite xylulose-5-phosphate. plays a role in 
the USF1-mediated transcriptional activation of human ACCI3 promoter. Here, 
PP2A inhibition attenuated USF1-mediated transactivation of the human ACCI3 
gene promoter in CV-1 fibroblasts. Surprisingly, PP2A inhibition also reduced 
USF1-mediated transactivation of the human ACCI3 gene promoter in neonatal 
cardiomyocytes. Furthermore. endogenous USF1 transcriptional activity was 
also reduced following exposure to okadaic add. 
Xll 
Since four E-box sequence elements were previously identified on the human 
ACCI) gene promoter, we next performed cotransfection studies with a USF1 
overexpression vector to determine sequence elements responsible for the 
USF1-mediated transactivation of the ACCI) gene promoter. Employing deletion 
constructs, we found that the shortest ACCI) promoter deletion construct was 
able to induce ACCI) promoter activity in both cell lines. However, the induction 
was reduced compared to the full-length construct indicating that the observed 
USF1 induction may be mediated via E-box 4 interacting with other upstream 
regions of the promoter predominantly through E-box 4 located close to the 
transcription start site. In summary, these data show that glucose-mediated 
USF1 induction of the human ACCI) gene promoter occurs in a cell-specific 
manner. In CV-1 fibroblasts, USF1 transactivates the human ACCI) promoter in 
a glucose-dependent manner, in part via dephosphorylation of USF1 by PP2A. 
On the other hand, USF1-mediated induction of ACCI) also occurs through 
dephosphorylation of USF1 by PP2A, although unlike CV-1 fibroblasts, glucose 
metabolites do not appear to mediate this process. 
We also found that NRF1 overexpression markedly attenuated ACCI) promoter 
activity in neonatal cardiomyocytes and cardiac-derived H9C2 myoblasts. 
However, NRF1 overexpression induced ACCI) promoter activity in both CV-1 
fibroblasts and HepG2 hepatocytes. Interestingly. we found that USF1-mediated 
induction of ACCI) promoter activity was markedly attenuated in all cell lines 
tested. We therefore propose that NRF1 may interfere with USF1 binding of the 
ACCI) gene promoter binding, probably via E-box4 located close to the 
transcription start site. In summary, we suggest that under energy sparing 
conditions, the transcriptional modulator NRF1 not only induces genes required 
for mitochondrial biogenesis, but can also negatively regulate ACCI) gene 
expression. This in turn should result in reduced malonyl-CoA levels and 
elevated mitochondrial fatty acid oxidation 
xiii 
In conclusion, we have identified a novel transactivator (USF1) and repressor 
(NRF1) of the human ACCI3 gene promoter in the heart. Our data may 
eventually result in the development of novel therapeutic interventions since we 
have identified unique modulators regulating ACCI3 gene transcription, and by 





1.1. Metabolism and the heart 
1.1.1. Glucose metabolism 
The normal, adult mammalian heart relies mainly on fatty acids (FA) as a fuel 
substrate. However, glucose also serves as an important fuel substrate, for e.g. 
when cells are placed under stress conditions such as hypoxia or ischemia. 
Blood glucose is taken up by via glucose transporters situated on the plasma 
membrane of the cell. There are several glucose transporter isoforms and their 
expression is dependent on developmental stage and tissue type.1-3 The fetal 
isoform is glucose transporter 1 (GLUT1) and the two well described adult 
isoforms, GLUT2 and GLUT4, are predominantly expressed in the liver and 
heart, respectively.1-4 In the heart and skeletal muscle, insulin stimulates 
translocation of GLUT 4 from intracellular vesicles to the plasma membrane in 
order to facilitate transportation of glucose into the cell2, 3, 5 (Figure 1). 
Inside the cell, glucose is rapidly converted into glucose-6-phosphate (G-6-P) by 
hexokinase. a rate-limiting and energy requiring step of glucose metabolism. At 
this stage, the fate of G-6-P is either glycolysis, the pentose phosphate pathway 
(PPP) or the hexosamine biosynthetic pathway (HBP), depending on a variety of 
conditions.6• 7 Under normal circumstances, G-6-P undergoes glycolysis where it 
is converted into fructose-6-phosphate (F-6-P), which is then converted into 
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Figure 1. A simplified schematic representation of glucose metabolism 
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Figure 4. A simplified schematic representation of mitochondrial oxidative 
phosphorylation. The thin black line represents the outer mi tochondrial membrane 
while the thIcker blue band represents tl1e lOner mItochondrial membrane. 





1.1.3. The gl ucose-filtty ilcld cyc le ilnd its physiologi(: ill rclCVilnce 
The preferenhal utlllzalion of glucose versus FAs (and Vice versa) \lI)der val)'rng 
physiological conditions forms the basIs of the glucose-faUy aCid cycle, inihally 
deSCribed b~ Randle'" (Figure 5) Randle et a1 27~ showed that FFAs rnlubllory 
effect on glucose metabolism was mediated via inhibition of glucose transport, 
glycolysis and pyruvate o~ldation. Others extended this hypotheSIS and revealed 
Ihat glucose avai labil ity can have an Inl,illltol)' effect on FAO 175 lntereshngly the 
mechanism for this Inhibitory effect of glucose has been proposed to be through 
increased formation of malonyt-CoA (proc1ucl 01 ACC) and subsequent rnhlbltion 
of CPT1 In summaI)' Ihe glucose-latty acid cycle suggests that availability of 
free fatty acids promotes fatly acid oxidation and subsequently il1hibits glucose 
oXldatloll Moreover the reverse" Randle effect proposes Ihat glucose 
availability promotes glucose oxidatlOO subsequel1t1y Il1hlbiling fally aCid 
oxidation 
I Glue,," me!abohm I 
GLUCOSE ''A 
Figure 5. A simplified schematic representation of the glucose-falty acid 
cycl C!. Abbrevla!lon free fatly acids iFFA) 
Cardiac fuel substrate ullllZ8tlOfl can be altered in response to a variety of 
physiologic ami pathophYSiologic condltions.33-311 FQ( example. during the fetal to 
adult transltlOll the major energy source of the heart switches from carbohydrates 
to FAs. During this period, plasma FFA levels are elevated and systernicgJucose 
levels reduced In parallel. The heart responds to such whole-body metabolic 
remodelirlg by enhancing Its capacity for FAO and concomtlanUy reduCIng 
glucose oxidation.:III Conversely, previous studies have demonstrated reduced 
FA utilization and a corresponding Increase In glucose uUlization dunng hypoxJ3, 
cardiac hypertrophy and heart faHure )4 .l$. "O-4l FQ( e)(8ITJple. glucose is 
proposed to inhibit CPT1~~ and thereforo FAO possibly via activation of ACe and 
subsequent elevatK)ll of Intracellular levels of malon~-eoA. a potent inhibitor of 
CPT1.-a Also, high cart>ohydrate feedlng after an acute fast increased ACC 
expresSion in the livet" · 50 and lowered lCFA-CoA levelsu AddlIJonaliy, insulin 
inhibits the release of FFAs from the adipose tissue thereby leading to decreased 
NEFA levers and attenuated FAO ~" ':0:1 On the other hand, Increased NEFA 
levels are aSSOCiated with activation of PDK4, an Inhibitor of the PDC complex, 
rasulIJng in Inhibition of glucose oxidation .$;! POK4 Is activated during high fat 
feeding and diabetes, conditions where glucose metabolism Is impaired.~511 
Saddick el al.~1 showed that administration of dichloroacetale (DCA), a POC 
sttmulator. to perfused hearts suppressed FAO via activation cA the muscle- and 
CSfdlac-enriched ACC Isoform (ACCIJ), and the subsequent Increase in malonyl-
CoA levels. Moreover, acrumuiatioo of NEFA levels further Impairs glucose 
tolerance and decrease muscle Insuhn S6IlSiUvily in high fat feedlOg and diabetic 
Il 
rats.~ CoIlechvely. these data underscore the signifICance of metabolic 
plasllcity of lhe mammalian heart and its innate ability to respond 10 physiologic 
and patOOph)'Sloiogic fuel substrate swi tches. 
1.2. Metabolic remodeling 
1.2.1. An odyssey of metabolic remodeling 
Metabolic remodeling is suggested to be part of an adaptive response under 
energy-limillng conditions and is regulated In response to developmenlal. 
hormonal or physiologiCllj stimulI. During the past few decades. researchers have 
investigated several aspects of metabolic remodeting including fetal to adult 
transition. physiological remodeling. development of cardiac hypertrophy. 
progression of cardiac hypertrophy to heart failure and diabetic remodellng.34. lS. 
~, 
a) Felal l o aduiliransition 
Duing the fetal to adult transition. the major energy source of the heart switches 
from glucose to FAs Here. fetal hearts demonstrated Increased myocardial 
glucose o~ldalion and lower FAa compared to nOYA>om hearts. In contrast. 
newborn hearts e~hibited increased myocardial FAa and lower glucose oxidation 
compared 10 fetal hearts.51 This metabolic SW1 tch is paraNeled by Induction of 
FAa genes and a concomitant redudJOn in the expression of genes involved in 
glucose metabolism. For e~ample. Nau et at U Observed a postnatal decline in 
expression patterns of glycolytic genes such as a-enolase. lactate 
dehydrogenase A and liver-type PFK whereas mitochondrial oxidative genes 
such as cytochrome c, COX Va and CPT1 wefe Increased, 
5' adenosine monophosphale protein kinase (AMPK) has previously been shown 
10 increase FAO by phosphorylatioo and Inhibition of ACC,6J.41~ In support, 
Maklnde el el.M demOOSlrated higher FAO rates In 1-day old rabbit hearts 
compared 10 1-day Old heans were associated With Increased AMPK and 
reduced ACC achvities, Although these studies did not Investigate the role of 
CPT1 in cardiac development, It appears that expresSIOn levels of muscle- type 
CPT! (mepT!) are low al birth and are upregulated durtng the postnatal 
development.~1 
These data highlight the IInportance of understanding Ihe metaOOlic transition 
from fetal to adult In the hean since some pathological conditions such cardiac 
hypertrophy are aSSOCIated 'Mth a reversloo to the fetal program, proposed to be 
pan of an adaptive mechanism, 
b) PhysiOlogical remodel ing and mitochondrial biogenesis 
The milochondoon is regarded as the 'pawer-house' of a cell since it generales 
about 90% of the energy required for chemical and metabolic processes that lake 
place in a liVing organlsm,Ga Therefore, failure to respond to energy demands 
eithef due to mutations In mitochondrial DNA or functional abnormalities can 
result in a variety of diseases sudl as childhood cardlOm~pathy 8l1d sudden 
death, diabetes mellitus, Ischemic heart disease. cardiac hypertrophy and heart 
faHure.!i$-ll.14 
I' 
Under energetic stress conditions such as endurance exerCIse, severe hypoxia, 
fasting or postnatal develop1lent, heart and skeletal muscle respond by 
increasing bioenergetic capacity.'S<71 This adap«ive response is characteriZed by 
in(;(eased expression of nuclear and milochoodrial enzyme-encoding genes and 
an inctease in number and size of the mitochondria, referred to as mitochondrial 
biogenesis. Since mitochondrial bioenergetiC capaCIty Is such a critical factor In 
Ihe celt's sUNivai and response 10 stress COnditiOns, the regula tion of nuclear and 
mitochondrial enz~e-encodlng genes must be under stringent control . Scarpulla 
and co-workers highlighted the role of nuclear respiratory factOfS {NRFI and 
NRF2} as important transcriptional modulators thai Induce nuclear genes 
encoding respira tory chain pl"otelns and regulatory faclors modulate 
mltochondnal-encoded genes.lUl In support, prevIOUS studies have 
demonstrated that NRFI induces mitochondrial transcription and replica lJon via 
activation of mitochondrial Transcription factor A (TFAM}_82 Also, TFAM 
overexpressmg mice were reSistant to teft ventricular (LV) remodeling and 
mproved LV function post myocardial infarclion_tJ 
On the other hand. NRFI augments FAD and oxidative phosphor)1atlon enzyme-
encoding genes through its interaction with a FA-responsive nuclear transcription 
factor, peroxisome proliferator·aclivated receptor (PPAR) 0 and its transcriptional 
coactlvator, peroxisome prollferator-activated gamma coactJVator (PGC) 10 02,03, 
GI &I .. Impor1anlly, impaired mitochondrial function observed With conditionS 
such as obeslty and dlabeles has been attributed to atteouated expression of 
PGCl and NRF1 .81 ae. However. it has not been fully established whether NRFI 
has direct invotvement In the regulatory controt mechanism of FA importation into 
the mitochondriOn. Other investigators revealed that increased NRF1 expression 
was associated with elevated CPT1 gene expression.lI9· 90 Pharmacological 
activation of AMPK was also associated with Increased NRFI promotE!!" 
binding 91 Furthermore. energy-sparing conditions such as endurance exercise 
have been shown to increase mitochondriat respiratory capacity and stimulate 
FAO in an NRFlIPGCl dependent manner.fIIl Interestingly. ACC~, an Indirect 
inhibitor of FAO. is suppressed following endurarJ(:e exercise. Al though these 
studies suggest a direct link between NRFI and FAO genes. whether NRF1 Is 
involved In transcriptional mechanisms driving regulation 01 ACCI'> remains 
unclear. 
cl Cardiac hypertrophy and heart failure 
Metabolic remodellng has also been demonstrated as a feature of cardiac 
hypertrophy. Previous investigators have reported increased dependence on 
glucose as a substrate with a concomitant decrease in FAO in hypertrophied 
hearts.92-94 This substrate switch is paralleled by a redudlon in FAO enzyme-
encoding genes and the re-emergence of the fetal gene program.35. 36. 115 For 
example. reduclion in the expression 01 GLUT4 and re-expression of GLUT1 
(fetal isoform) has been previously reported 96. !17 Moreover. earher studies 
indicated that glycolytic enzymes such as he~okinase and lactate dehydrogenase 
paralleled Increased preferential glucose utillzalion with cardiac hypertrophY,:l5 
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while increased e~pressiOl1 and activity of AMPK was associated With higher 
basal glucose uptake 'Nith left ventricular hypertrophy.~ 
In contrast. the reduction in FAD observed with cardiac hypertrophy is paralleled 
by suppression of a number of FAD responsive genes such as FAT/CD36, MCD. 
PDK4, mCPT1. MCAD, LCA$.43. IlII-l02 This coordinate downregulation of FAD 
responsive genes has largely been attributed to reduced PPARa expression.99. 
1~3 Funhermore. reduction of PPARo during cardiac hypenrophy has been 
directly hnked to preserved contractile function since its reactivation diminished 
cardiac contractile functlon.:l9 
The failing heart has also been shown to shift towards preferential utilization of 
glucose.:loI· I~ 10!5 For example. Razeghl et al. 1OO proposed that the failing heart 
sWItches to the fetal gene program by reduction of adult gene isoforms such as 
GLUT4 and muscle CPT1 rather than the Induction of fetal gene expression. 
Here, the expression of felal gene isoforms such as GLUT1 and I-CPTl was 
unchanged in failing human hearts compared to fetal hearts_ On the other hand, 
other Investigators observed a downregulalion of several FA utilization genes In 
the failing heart.9II· ,o1 However, Chandler et al. 108 found no differences in 
myocardial substrate metabolism in a dog model of moclerale coronary 
mlcroembolizaUon-induced heart failure. The authors suggested that the switch 
to a fetal gene program may depend on the severity of heart failure i.e. there is 
no decrease In FAO in their model since it represents compensated heart failure. 
The observed switch to carbohydrate oxidation may therefore be a late-stage 
phenomenon If this is correct, reports of overstimulatlon of the adrenergic 
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system with heartla~ure and the elevation 01 FFA levels may represent an earlier 
point in tefTllS 01 the progression 10 heart la ~ llre. It has recently been 
hypothesized that under these condibons UCPs uncouple mitodloodrial 
respiration leading to oxygen wastage and reduced cardiac effidency.1011 Hence, 
the mechanism of action of phannacotogical Inhibitors of FAD, a potential 
treatment for heart lallure, 110 Is thoughl to be due to an indirect increase In 
glucose Oxidation and decreased FA-induced oxygen wastage. 10\1. It t 
d) Diabetes 
Several studies have reported thai diabetic hearts demonstrate severely 
diminished glucose uptake and a mar1<.ed reliance on FAD 10 meet energetic 
requlrements,52. m. 113 Moreover, intracellular accumulatlOO of NEFA levels 
further impair glucose tOlerance and decrease muscle insulin sensitivity in high 
lat leeding and diabetic rats 5S-«I As a consequence of diabetiC remodeling, the 
expressioo of genes involved in glucose metabolism is suppressed whereas FA-
respoo5lve genes are upregulated ~1 For example, cardiac. GlUT4 expresslon is 
reduCed while both hexokmase and POC enZ)'me actMty were diminished in 
diabetic rat hearts 114. t15 Intracellular FA accumulation during diabetes is 
thought 10 activate PPARo and PGClo, which In tum induce the expression FAO 
genes such as FAT, mCPTt, MCAD, PDK4, and MCO.·3.5' 101 This could explain 
reduced glucose metabolism and mar1<.eclly increased FAO rates exhibited by 
perfused diabetic hearts "6 111 Inaeased POK4 expression Is thought to be 
responsible lor reduced POC actiVity ooserved In diabetic rat hearts. In contrast, 
some have argued that reduced POe activity is due 10 accumulation of FAO 
products rather than the phosphorylated stale of POC comptex 11 8 
Lastly, chronically diabetic subjects were characlefized by a reductIOn of genes 
involved in oxidative metabolism for e,g. PGCl , CPTl , citrate synthase (CS) and 
cytOChrome C oxidase (COX) 11,119 In suppofl, other Invesllgalors have fuflher 
suggested that reduced PGCl and NRFI levets may be contribute to the 
accumulation of intracellUlar lipids and decreased FAO !ia Again, differences In 
substrate metabolism may be due to the stage of the disease. It has also been 
suggested that reduced FAO observed In certain type 2 diabellc patients may be 
attnbuted to increased gene expression of ACCIl and subsequent accumulation 
of malonyl-CoA levels.'m. '2' 
1.3. Transcriptional regulation of metabolic remodeling 
As descnbed In the previous sadion, metabolic remodeling may occur in several 
phySIologic and pathophYSIOlogic contexts. Several investigators suggested that 
metabolic remodeling is dnven by changes In the expression of metabolic genes. 
However, the molecular mechanisms underlying regulation and conlrol of several 
putative metaboliC genes are currently being Investigated. For example, at the 
transcrlptlonal level recent studies have suggested that nutrient-sensing 
transcriptional modulalofs thai regulate glucose and FA utili;ul tion genes may 
playa pivotal role in OOvII19 metabolic remocieling processes.20·H m·ll!; 
1.3.1 , Fatly acid mediated transcriptional regulation 
Recent studies have Idenllfied PPARs, the ligand-activated nuclear receptor 
family of transcription factors, as key modulators that Induce the expression of 
FAO genes,20, 41 , 124 125 Thus far , three PPAR lsoforms have been identified, 
namely: PPARa. ~I('j and y. PPARa IS predominantly expressed in highly 
oxidative tiSSUes like liver, heart and skeletal muscle. while PPARI3I('j is 
ubiquitously expressed and has been implicated in the regulation of FAO.125, 126 
Conversely. PPARy is highly expressed in lipogenic tissues such liver. white and 
brown adipose tissue, PPARy Is thought to playa role in thennogenesis, lipid 
storage and glucose metabolism 
PPARs consist of a DNA-binding domain containing two Zn-finger motifs and a 
C·terminal domain lor ligand binding. Upon binding Its ligand, PPAR 
heterodimerizes with its obligate partner, retinoid X receptor (RXR), subsequenlly 
binding to pero~isome-proliferator response elements (PPRE) located within the 
regulatory region 01 target genes. PPARs can bind both endogenClJs and 
exogenous ligands such as long chain FAs and fibrates. respectively, RXR is 
also activated In a IIgand-dependent manner I.e. 9-cis retinoic acid serving as Its 
ligand . 
a) ligand-activated PPARo regulates fatty acid oxidation 
The use of synthetic ligands such as librates and Wy-14,643, and PPARa null 
mice have contributed tremendously In Identifying a key role for PPARo in 
cardiac FA utilization ,I27·12!l Moreover, endogenous ligands such as LCFAs 
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mediate metabolIC changes via activatIOn of PPARa m. 1)1) Here, PPARa has 
been shown to Induce gene e~presSion of cardiac FA transport proteins such as 
FATP, FAT/CD36 alld FABP'J' and FAD via the induction of CPT1 and MCAD 
gene expression ~l PDK4 was also Identitied as a PPARo target gene since Its 
gene expresSion and activ ity was Increased in response to PPARo st imulation ~~ 
High filt feeding, fas!lng ond dlilbetes howe been shown to ,"crease FFA levels, 
PPARa ilnd subsequent activation of FA responsive genes such as CPT1 , 
MeAD and PDK4 " a, ';19 On the contrary, downregulallon of FAO genes during 
hypoxIc exposure has been atli lbuted to deacllvatlon of PPARo, a ma)Of 
transcriptional modulatQ( of FA responsive genes In the rat heart 4, ,De 
Moreover PPARo null mice exhibit low FAO rates pa,slleled by a malked 
reducUon in several FA responsive PPARa-regulilted genes ,;of, 12\1 Together 
Ihese data show Ihal PPARa IS a pivotal regulato! of severat cardiac FA 
utl lizalJon genes. 
b) Ligand-activated PPARIVO regulates fatty acid oxidatioll 
Thus far the tranSCflpllOnal role of PPAR~O IS not as well understood 
PPARJ3,IO Is ubiquitously expressed , with higher levels of expreSSIOn In Ihe brain 
adipose tissue and skm .'l'& m 1)2 Recently PPAR~O has been demonstlated 10 
regulate Ihe expression of genes involved in FAO III Skeletal muscle cells.13J ,34 
Moreover. both PPARo and PPARJ3,IO acllvale FAO in cultured neonatal and 
adult myocytes Ie" PPARJ3,IO expression IS regulated by nutntlOnal status. r]S Like 
PPARo. PPARJ3!O Is actIVated by lCFAs and has also been implicated in the 
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regulation of genes involved in sarcolemmal FA up/aile (FATP and FAT)I:III and 
milochondnal FA uplake (CPT1). 131 Th~ dala Wggestlhat lhere may be some 
redundancy in lerms of PPAR act!VaOOo :)f cardiac FA ulJlization, However, Ihe 
precISe Interplay between PPARo and PPARjMO In temlS d regutatlon 01 FAO 
genes still needs to be determined 
1.4. Glucose as a transcriptional regulator 
Glucose has classically been considored as a metabolic substrate that provides 
energy to lhe celt especially under energy sparing conditions such as exercise.'Ja 
and ischemla. l :!9 1<0 However. recent studes show that glucose may also proVide 
signals \0 glucose responsive factors to drive transcriptional activation of genes 
involved in glucose metabolism and llpogenesls. l22 '23 For example. the 
gl~lytic liver type pyruvate kinase (LPK) gene was upregulated with high 
glucose exposure In hepatocytes'u or high carbohydrate releadlng.'·' 
Furthermore. an Inaease in glucose levels foflowing high carbohydrate refeading 
was aSSOCiated with induction of rat liver 6-phosphofructo-2·kinaseffructose-2.6· 
bisphosp/latase gene expression."~ In &ddition expression 01 lipogenic genes 
such as fatty acid synthase (FAS) and ACCo were reduced by an acute fast but 
upregulated following h,g, carbohydrate refeeding. l22. "I Glucose has also been 
shown to induce the gene expression of S14. a lipogenic protem, in the liver.IOJ 
These glucose.mediated gene transaiptional effects are suggested to occur via 
specific glucose-sensing transcriptional modulators aOle to bind consensus 
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regulatOf)' regions withm promoters of target genes. Glucose-responSive 
tranS(;riptlon factors indude carbohydrate response element binding protein 
(ChREBP),'" '.5 sterol regulatory elameot binding protein 1 (SREBPll.'08 ,0/ 
stimulatory protein 1 (Spl )'08 and upstream stimulatory factors (USF 1 and USF2 
fsoforms).122. ,., Moreover. ChoRE, a glucose-inducible promoter region, was 
demonstrated as a key transcnptional regulatOf)' region of ACCa. FAS afld S1 4 
In response to glucose '~ 151 For example. ChREBP was identified as the key 
glucose-responSive modulator that bnds 10 ChoRE regioo of LPK gene 
promoter.' .... '.5 Previous investigators h<Ne damMstrated Ihal USFII2 isoforms 
and ChREBP bind E·box sequence motifs (CAANTG) as homo and/or 
heterodimers on promoter regions with subsequent Induction 01 target genes 150. 
1~·1$1 Furthennore, Wang at aI.'!oII demonstrated markedly increased USF1 
protein expression upon high carl>ohydrate refeeding following an acute fast. In 
mice lacking USF1. glucose mediated stlmulatioo 01 LPK and S14 genes is 
partially reduced and ccrnpensated for by USF2.'22. 109 Furthermore. USF2 null 
mice displayed an impaired glucose responsiveness 01 glucose-iflduced genes. 
These data suggest that USFs play a crucial role in glucose-mediated 
transcriptional responses '~ 
Some researchers have suggested that glucose metabolites and intermediates 
such as G-6-P and X-S-P, and not gluccse per se, are responsible for glucose 
mediated tranSCriptiOnal acllvatlon of genes 155. 1110. lei In agreement, G-6·p has 
been demonstrated to ocbvale transcription of largel genes. Ie:- tn support ollhis 
c:oncept, 3·O-methyt glucose. a glucose analog that is taken up by the cells but 
cannot be phosphorylated, failed to increase the expression of FAS and ACCa,11 
In addition, 2-deoxyglucose, a glucose analog that is taken up but can be 
phosphorylated, stimulates FAS gene expression in cultured white adipose 
tissue,155.16o Furthermore, X-5-P, an intermediate in pentose phosphate pathway, 
increased transcription of genes involved in lipogenesis, hexosamine 
monophosphate shunt and glycolysis,9. 163. 164 X-5-P stimulates PP2A 161 thereby 
promoting translocation of ChREBP into the nucleus where it binds to ChoRE on 
the promoter of the LPK gene.10. 11. 13 Also, PP2A dephosphorylates and 
activates ACCa in most tissues.165. 166 In agreement with this concept, ACCa was 
transcriptionally activated by glucose148 in pancreatic beta cells via activation of 
Sp1.148 Together these data implicate glucose and/or its metabolites as 
important signaling molecules in the induction of glucose responsive genes. 
1.5. AMPK as a transcriptional regulator 
Under conditions of increased (AMP/ATP) for e.g. exercise or hypoxia, AMPK is 
activated and ACC subsequently inactivated (by phosphorylation) in the liver and 
FAO hepatoma cells,167. 168 It has recently been shown that AMPK is activated in 
response to energetic stress to increase bioenergetic capacity, For example, 
increased AMPK activity has been shown to elevate glucose uptake by GLUT4 
translocation and stimulate FAO by inhibition of ACCJ3 169-171, Recently, AMPK 
has been demonstrated as a direct link between intracellular stress signals and 
the regulation of gene transcription. For example, addition of AICAR (AMPK 
activator) downregulates the expression of GLUT2, aldolase Band LPK genes in 
25 
pancreatic ~ cells. 172-174 AICAR administration in hepatocytes also resulted in 
decreased expression of FAS, PEPCK and G-6-P genes. 174. 175 Increased AMPK 
activity in the liver also resulted in upregulation of CPT1 176 
These AMPK effects have been suggested to be mediated via direct activation of 
nuclear transcription factors that either activate or repress transcription of target 
genes.177 For example, it has been shown that AMPK represses PPARy-
mediated transcriptional activity.177 On the other hand, AMPK activates PPARa-
mediated transcriptional regulation. 178 In addition, ~-GPA (indirect AMPK 
activator) activation of AMPK was associated with increased binding activity of 
NRF1 to the promoter of a target gene.91 Recent evidence has also shown that 
AMPK phosphorylates and inhibits transcriptional activity of ChREBP.13 AICAR 
administration to hepatocytes repressed the induction of LPK gene expression by 
attenuating the transcriptional activity of hepatocyte nuclear factor 4 (HNF4 ).173. 
177 Moreover, AMPKa-l- mice were characterized by a downregulation of several 
genes involved in both glucose transport and FA utilization.179 These data 
therefore indicate that AMPK could be a direct link between intracellular stress 
signals and the regulation of gene transcription. 
1.6. The role of acetyl-CoA carboxylase in substrate metabolism 
Acetyl-CoA carboxylase (ACC) catalyzes the carboxylation of acetyl-CoA to form 
malonyl-CoA, a potent inhibitor of CPT1. At least two ACC isoforms (ACCu and 
ACC~) exist in mammals. The ACCu gene encodes a 265-kDa isoenzymic form 
that is predominantly expressed in lipogenic tissues such as the liver and 
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adipose tissue.23-25 In contrast, ACCJ3 encodes a 280-kDa isoenzymic form that 
is mainly expressed in non-lipogenic tissues such as the heart and the skeletal 
muscle.26,27 The catalytic portion of ACCJ3 is similar to that of ACCa except for 
an additional 150 amino acids at the N-terminus. The N-terminus is believed to 
be responsible for interacting with the outer membrane of mitochondria where it 
controls mitochondrial FA transfer by producing malonyl-CoA near its CPT1 
binding site.180, 181 Since both ACC isoforms produce malonyl-CoA, it is believed 
that malonyl-CoA produced by ACCa is essential for FA biosynthesis while 
malonyl-CoA produced by ACCJ3 regulates mitochondrial FA oxidation pathways. 
ACCa gene regulation has been extensively characterized (reviewed by 
Taegtmeyer and others)22, 95, 182 and multiple levels of control have been 
determined for its regulation in the FA biosynthetic pathway.181 At the 
transcriptional level, ACCa is regulated by two promoters, PI and PII. PI is 
regulated under lipogenic conditions such as high carbohydrate feeding,183, 184 
while PII is regulated by insulin, cAMP and tumor necrosis factor.185, 186 
Interestingly, PII contains glucose responsive elements and Sp1 sites which are 
thought to mediated glucose-induced transcriptional activation of ACCa. 187, 188 
Since very little or de novo fatty acid synthesis occurs in non-lipogenic tissues 
and as malonyl-CoA has been demonstrated as a potent inhibitor of CPT1, this 
strongly suggests a distinct role for ACCJ3 in the regulation of mitochondrial FAO 
in the heart and skeletal muscle.189-191 Therefore, ACCJ3 must be subject to 
stringent regulatory control mechanisms at both transcriptional and translational 
levels. 
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1.6.1. Metabolic regulation of the cardiac isoform of acetyl·CoA 
carboxylase (ACCP) 
Previous investigators have demonstrated that in vitro and in vivo ACCJ3 activity 
is inhibited by reversible phosphorylation. Here, AMPK and PKA have been 
identified as the two main enzymes involved in phosphorylation and inhibition of 
ACCJ3 activity (Figure 6). AMPK phosphorylates ACCa at Ser79, Ser1200 and 
Ser1215 phosphorylation sites while PKA phosphorylates ACCa at Ser77 and 
Ser1200.192 Interestingly, these phosphorylation sites are preserved on ACCJ3.27. 
165. 166. 192 In addition, phosphorylation sites for protein kinase C and casein 
kinase II have been identified on the N-terminal region of ACCJ3.18o It is also 
important to note that phosphorylation of both ACC isoforms can be reversed by 
protein phosphatases 2A and 2C.165. 166. 193 The activation of protein 
phosphatases is thought to be mediated by glucose and/or insulin.10. 11. 13. 194 
As shown in Figure 6, the formation of malonyl-CoA by ACC can be reversed 
through decarboxylation by malonyl-CoA decarboxylase (MCD). Increased MCD 
gene expression and activity result in reduced malonyl-CoA levels thereby 
promoting FAO. Some investigators have reported that FAO-promoting 
conditions such as fasting and high-fat feeding increase cardiac MCD gene 
expression.276 MCD is also a PPARa target gene, for example, administration of 
PPARa agonists resulted in the induction of MCD expression (at gene and 
protein level) and activity.276 Moreover, downregulation of cardiac MCD 
expression (gene and protein) and activity was observed in PPARa-l- mice.277 
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Post-transcriptionally, MCD is phosphorylated and activated by AMPK which is in 
tum activated in response to ischemia278 and exercise.252 
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Figure 6. A schematic representation showing metabolic regulatory 
mechanism of acetyl-CoA carboxylase. Abbreviation: free fatty acids (FFA), 5' 
adenosine monophosphate protein kinase (AMPK), protein kinase A (PKA), acetyl-CoA 
carboxylase (ACC), malonyl-CoA decarboxylase (MCO), carnitine palmitoyl transferase 
1 12 (CPT 1 12). 
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Under energy-sparing conditions for e.g. ischemia and exercise, activation of 
AMPK and PKA result in phosphorylation and inhibition of ACCJ3 and subsequent 
lowering of malonyl-CoA levels.193, 195-199 In support, Abu-Elheiga et al.200 
observed reduced malonyl-CoA levels following a 48 hour fast in the liver, 
skeletal muscle and the heart, leading to the conclusion that both ACC isoforms 
must be regulated by nutritional flux.2oo, 201 Furthermore, administration of AICAR 
to perfused rat hind limbs lead to a reduction in ACCJ3 activity and intracellular 
malonyl-CoA levels, thereby increasing FAO.202 Also, insulin, epinephrine, 
glucagon, leptin, citrate, acetyl-CoA levels, LCFA and malonyl-CoA have also 
been implicated as important post-translational regulators of ACC activity.26, 57, 
165,181,203-205 
Since the regulation of ACC activity by allosteric activation (citrate) and covalent 
modification of enzymes i.e. by phosphorylation/dephosphorylation lasts for 
seconds to minutes, maintenance of ACC activity for hours to days must be 
regulated by changes in gene expression.165, 181, 194, 203, 204, 206 In support, ACCJ3 
gene and protein expression were upregulated following exposure to glucose and 
ciprofibrate, a PPARa agonist.18o Moreover, ACCJ3 gene expression in the rat 
liver was downregulated following a 48 hour fast and markedly increased 
following 24-48 hour refeeding with a fat-free high carbohydrate diet.18o, 194 
Interestingly, H9C2 myoblasts do not express ACCJ3 while differentiated H9C2 
myotubes highly express ACCJ3, underscoring the importance of controlling FAO 
in the developing and an adult hearts.18o, 207 Moreover, ACCJ3 null mice are 
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characterized by low malonyl-CoA levels and a subsequent increase in FAO 
rates in skeletal and cardiac tissues.2oo When ACC~ null mice were challenged 
with a diabetes/ obesity-inducing diet (high-fatlhigh-carbohydrate), they were 
protected against diabetes and resistant to weight gain compared to wild-type 
mice.194 This was evidenced by a number of factors including decreased fat 
content, efficient glucose clearance and high insulin sensitivity (reduced glucose 
and insulin levels) and attenuated levels.194. 200 Collectively, these data 
underscore the importance of understanding transcriptional regulatory machinery 
of ACC~ and its role in the regulation of FAO. In this regard, characterization of 
the recently cloned human ACC~ promoter180. 208 requires further attention in 
order to advance our understanding of the regulation of ACC~ gene expression. 
1.6.2. Transcriptional regulation of human ACCP promoter 
Most muscle-specific genes have multiple E-boxes (CANNTG) in their promoters 
that bind muscle specific factors and regulate their gene transcription.209 Since 
ACC~ is highly expressed in the skeletal muscle and the heart, Lee and 
coworkers208 analyzed the human ACC~ promoter for novel CANNTG binding 
sites. Here, at least four E-box consensus sequences were identified.208 These 
studies revealed that MyoD, a member of the muscle regulatory factor family, 
induces ACC~ expression by binding to E-box consensus motifs located on the 
ACC~ promoter.208 Furthermore, Sp1, a glucose responsive transcriptional factor, 
inhibits MyoD mediated transcriptional of ACC~.208 Others have demonstrated 
that MyoD mediated transcriptional activation of ACC~ promoter was attenuated 
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by retinoic acid receptors, RXRa and RARa.207 Recently, SREBP1, a glucose-
responsive transcription factor thought to regulate expression of insulin and/or 
diet-induced genes in the liver, has been implicated in transcriptional activation of 
ACCj3.194 
1.7. The role of ACCP in metabolic remodeling 
Understanding the fundamental role of fuel substrate switches in the progression 
of cardiovascular diseases such as diabetic cardiomyopathy, cardiac hypertrophy 
and heart failure is important to the development of novel therapeutic 
interventions. As previously noted, the diabetes-induced shift in cardiac 
metabolism (increased FAO rates) triggers contractile dysfunction.116, 117 Some 
investigators have therefore argued that the use of phannacological inhibitors of 
FAO, as a potential treatment for heart failure may be due to an indirect increase 
in glucose oxidation and decreased fatty acid-induced mitochondrial oxygen 
wastage.109, 111 
These and other data highlight the importance of understanding the regulatory 
mechanisms underlying such fuel substrate switches in the heart. In light of this, 
ACCj3 has been identified as a key regulator of FAO since its product malonyl-
CoA potently deactivates CPT1. Moreover, ACCj3 null mice are resistant to 
diabetes and obesity-inducing diets, likely due to reduced malonyl-CoA 
production and therefore continuous elevation of FAO rates. 194, 200 In addition to 
ACCj3-mediated control of FAO, preferential utilization of one particular metabolic 
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fuel substrate by the heart will inhibit utilization of the other (Randle cycle). For 
example, glucose is thought to limit FAD by inhibiting FA importation into the 
mitochondrion. Together these data implicate ACCI3 as an important target for 
therapeutic interventions during pathophysiologic metabolic remodeling. 
Therefore, this thesis focused on further understanding transcriptional 
mechanisms regulating ACCI3 gene expression in the heart. 
Specifically, we hypothesized that (Figure 7): 
1. Increased glucose availability induces cardiac ACCP expression via 
USF1 J a glucose-responsive transcription factor 
2. NRF1, a transcription factor that promotes FAO, inhibits ACCP 
expression in the heart. 
34 
Metabo1ic remodeling 





J .,............. FA import into mitochondria 
r==? " 
FAO 
Figure 7. Schematic representation of hypotheses 
The objectives of the study were to: 
1) Determine in vivo cardiac ACC p, expression in response to high 
carbohydrate releeding 
2) Elucidate the transcript ional mechanisms regulating the human 
ACCp, gene promoter in response to increased glucose flux 
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Chapter 2 
The Human Gene Promoter of the Cardiac Isoform of 
Acetyl-CoA Carboxylase (ACCj3) is Transactivated by 
Upstream Stimulatory Factor 1 (USF1) in a Glucose-
dependent Manner 
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2.1 . Introduction 
The cardlac·enriChed isolorm of acetyl-CoA carboJlylase (ACCIJ) IS a key enzyme 
regulating mitochondrial FAO in the heart. However, unlike ACCu (enriched in 
lipogenic tissues), molecular mechanisms direcllng ACCI3 gene transcnptlon are 
unclear PrevIOUS studies reported increased ACCI3 gene expression In the liver 
of mice fed a high carbohydrate dIet 1M . 190< These data therefore assoclale 
elevated plasma glucose levels with increased ACCI3 gene expression In 
agreement, others have shown that glucose andlor metabolites of glucose 
metabolic pathways for e.g. the pentose phosphate and he~osamine biosynlhelic 
pathways playa role in medl<lting transcription of lipogenic genes. 121. III For 
e~ample . in termediale metabolites 01 Ihe pentose phosphate pathway I.e. 
glucose-6-phosphate (G-G-P) and xylulose-5-phosph<lle (X-5-P) have been 
Implicated In the transcriptional activation of several metabolic genes .• ». ' 111. 111 
Here. il has been proposed that Increased X-S·P levels may aclJvale a 
downstre.am larget, protein phosphatase 2A (PP2A) whICh in tum 
dephosphOl)1ates and activates specific transcnption factors for e.g . upstream 
sllmulatory factor 1 (USF1). Subsequenlly, acfivated glucose-sensing 
transcripliooal modulators bind specifIC cis-elements located within the promoter 
regions of lafget genes For example. It has been demonslrated Ihat USF1 
regulates gene Iranscriphon by binding to E-box sequence motifs (CANNTG ) 
located Within the promoter regloos of targel genes.122 
Recenlly, four E -bo~ consensus sequences were IdentJfied on the human ACCIJ 
gene promoter 2OO! In light of thiS. we hypothesIZed that USFI Induces ACCIJ 
gene transcriptIOn In the heart In a glucosf.KIependent manner. Moreover, we 
proposed that USF1-medlated Inducllon of ACCIJ gene transcnption occurs VIa 
the pentose phosphate pathway tn order to test the hypothesis, we Initially 
determined m villO cardiac ACCp gene and protem e~presSlon In mICE! fed a high 
carbohydrate diet after a pened of faslmg In agreement wJth our hypothesis. we 
found increased cardiac ACCIJ expression associated wdh elevated plasma 
glucose levels To further investigate thIS, we ne~t periormed a series of 
trnnsfeclion-based studIes usmg the human ACCp gene promoter alld a USF1 
expressiofl construct. Here, we transiently transfected various celt hnes i.e, 
neonatal cardiomyocytes and carthac-derived H9c2 myoblasts. and two cardiac· 
nun cell types ICV·l fibroblasts and HepG2 hepatocytes) with the full·length 
ACCIJ gene promoter construct and a USFI expressIon veclor under low (55 
mM) and high glucose (25 mM) cuttumg conditions 
In this study, we Identify USFI as a novel transaCllvator of the human ACCP 
gene promoter In three of the four cell lines tested (cardiomyocytes, CV·\ 
fibroblasts and HepG2 hepatocytes). Transienl transfeet ion studies WIth several 
ACCP gene promoter deletIOn and mutant constructs show lilal USF I·induced 
human ACCp promoter actIvIty is medIated through region -92 10 -39 and/or E-
box 4 (· 14 to -9) elements located in Itle first 569 bp upstream of the transcription 
start site Moreover, we found glucose-dependent USF I transaclivallon of Ihe 
J8 
human ACCI3 promoter 111 CV·1 fibroblasts and HepG2 hepatocyles OUr In vitro 
data also suggest the Involvement ofaxylulose-S-phosphateIPP2A mediated 
Signahng pathway that dlreas the transcriptional regulahon 01 the ACCI3 gene III 
CV·I fibroblasts 
2.2 , Materials and Methods 
2.2.1. In·vivo studies 
a) Animals 
BalblC female mice aged between 8-10 weel\s were housed at room temperature 
on a 12·hour darkll2·houf light cycle. The metabolic cages lacked bedding and 
contained a metal gud at the bottom of the eage to aVOId re-feeding on fecat 
matter, espeCIally during fasting. Mice were stabilized lor teo days with a 
commercially available control diet (19% protein, 10% fat. 4.3% tiber and 60.6% 
carbohydrates, catalog II 7024 (5755). Punna Mills. Richmond. IN). After 
stabilization. one groop continued to receive food ad libitum (oontrol group) willie 
the other mouse group was fasted for 48 hours and fe-fed a carbohydrate-
enriched diet (19% protein. 0"10 fat, 4.3% liber and 70.6% carbohydrates. catalog 
:I 7576 (5803). Purina Mills. Richmond. IN) (RHC group) for an additional 48 
hours. All animals had free access to dean water. In order to avoid any bi<:ls due 
to diurnal variations, preparations such as blood and tissue collection were 
roullnely performed between 16hOO and 18hOO. Mice were sacriliced after each 
experimental lime point using calbon dIOxide. Intact hearts were dissected out 
and stored at ·6O"C for subsequent molecular and biochemical analyses. The 
University of cape Town's Animal Research Ethics CommIttee approved all 
animal oKpenmenls and the investigation conforms to the Guide for the Care and 
Use of laboratory Animals published by the US Nationallnslitutes of Health (NIH 
Publication No. 85-23. revised 1996) 
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b) Determination of glucose levels 
Blood was collected by cardiac puncture from all expenmeotal giOOps. Samples 
were centrifuged al 3,500 rpm for 10 min and the supernatant collected. Plasma 
(50 ~I) glucose levels were measured uSlf'lg a spectrophotometnc gll.JC05e 
oxidase method described previously by Trinder et aI. (1969). 114 
c) RNA Isolation and Northern blot analysis 
RNA was extracted and punfl8d 9S descnbed prevIOusly " Northern blot analysis 
was performed by loading 20 ~ of total RNA in each lane, separated on a 
denaturing gel and transferred to a nylOfl membrane (Hybond N, Amersham 
Pharmacia Biotech, UK). After Iixallon, the membrane was probed With 
radiolabeled probes derIVed from cDNA fragmems encoding for ACCji. AI, 122· 
bp fragment of ACC ji was generated by RT·PCR using pnmers based on the 
ptlbhshed rat ACCfj cONA sequence (5'-TTCGATGTCCTGCCCACTTT·3' 
(forward) and S'-TGGTGATGAAGAGGCGAAT-3' (reverse),"$ 28 S rRNA 
transfer to nitrocellulose membrane was used 10 assess RNA integrily and to 
conlrot for variance in gel loading. The relative abundance of mRNA was 
determined by autoradiogaphy and quantlfl8d by laser densitometric analysis 
using the UV1Tec autoradiography analyzer with uvlband software v.97 
(Cambridge. UK). 
d ) Protein extraction and Western blot analysis 
Frozen heart tissue (60-80 mg) was briefly sooicaled in 400 III lysis buffer (10 
mM Tns, 5 mM EGTA, 0.1 mM OTT. pH 7.2) supplemenled with protease 
Inhibitors (2 mM PMSF. O. t25 flg/rnI leupeptin. 0.5% SOS). The homogenate 
was centrifuged at 5,000 rpm for 5 m!ll, the supernatant coIleded and protein 
concentrations determined using the Lowry method?16 Sixty fig of protein extract 
was used for ACe protein btotung analysis. Protem extracts were resol ... ed by 
SOS·polyaCl)1arnlde gel electrophoreSis (5%) and protein le ... els of the ACC 280-
kOa lsofonn detected by probing blots with horse radish peroxidase-labeled 
strepta ... idin (Klrkegaard & Perry Laboratories Inc .. Gaithersburg. MOJ. which 
binds biolin-containing carbox]'1ases. Equal protein loading was confirmed using 
Ponceau Red staining as described prevlously.m Protein bands were detected 
uSing a chemiluminescence system (Amersham Pharmacia Biotechnology. UK) 
and quantified by laser densitometric analysis using the UVITec autoradiography 
analyzer with uvlband software ... . 97 (Cambridge, UK). 
2.2.2. In vitro studios 
a) Cardiomyocytes 
Cardiomyocyles were iSolated from 1·3 day old Wlslar rats by collagenase/ 
pancrealln digestion and punfled using percoll density gradient centrifugation. 
Briefly. rats were Intraperitcneally anaesthetized wi th 0.2 ml sodium 
pentobarbitone. The rat hearts were exerdsed out and Immersed in 1X ADS 
buffer (6.8 9 NaCI. 0 4 9 KG!. 1 9 gluCXlSe. 0 17 9 NaH~PO •• 0 2 9 MgSO~. 4.76g 
HEPES in 1 L H~O . pH 7 4). The hearts were cut in half and washed twice with 
fresh 1X ADS buffer to remove blood . For the collagenase digestion. the hearts 
were finely cut into small pieceo;. placed into a 25 cm2 flao;k containing 10 ml 
collagenase solution (0.0225g collagenase D (394 Ulmg). 0.045 9 pancreatin in 
50 ml 1X ADS buffer} and incubated In a shaking water bath at 37"C for 15 
minutes. The supernatant was transferred into a 15 ml tube and cenlrifuged al 
300 x 9 at room temperature for 3 minutes. The pellet was resuspended in 2 ml 
newborn call serum (NBS) (Gibco. New Zealand) and incubated at 37"C (the 
collagenase digestion step was repeated until all of Ihe tissue was digested). The 
combined suspension was centrifuged at 300 x 9 for 3 minutes at room 
temperature. The pellet was resuspended in 4 ml of 1,082 glml of percoll solution 
(Amersham. South Africa), An equal volume of 1.062 91ml of percoll SOlution was 
then added on top of the suspension followed by centrifugation at 1.000 x g at 
room temperature for 3 minutes. Thereafter. cardiomyocytes were transferred 
into 1X ADS buffer and centrifuged at 300 x 9 at room temperature for 3 minutes. 
The pellet was suspended in Dulbecco's Modified Eagle's Medium (DMEM) 
(Hlghveld Biological. South Africa) supplemented with 20% letal calf serum (v/V) 
and 100 ~glml of penicillin/streptomycin. Each group of 20 neonatal rat hearts 
yielded approximately 16 x l OS cells/mt. Cardlomyocytes were subsequently 
plated in 12-well plates pre-coated With fibronectin (35 Il9lml) at a density of -8 x 
10' cells per well In DMEM. 
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b) CV-1 fibroblasts, H9C2 myoblasts and HepG2 hcpatocytes 
H9C2 rat heart-oerived myoblasts (ECACC no. 88092904), CV-l monkey kidney 
fibroblasls (ECACC no. 87032605) and HepG2 human Caucasian hepatocytes 
(ECACC no. 85011430) were seeded in 75 cm2 flasks until they reached 70-80% 
coofluency. Thereafter, the medium was removed and cells were washed wllh 5 
ml I X PBS (8 g NaCI , 0.2g KCI, 1.44 g N3;!HPO., 0.24 g KH. PO. in 1 L. pH 7.4). 
The ceils were trypsinized With 5 ml of 0.25% trypsin (Hlghveid Biological , South 
Africa) and 0.2% EDTA (Sigma. Germany) and Incubated at 37"C for 3 minutes. 
Following incubatiOn. 10 ml of medium was added and cells were transferred into 
a 50 ml tube and centrifuged at 1.000 rpm for 5 minutes. Cells were then plated 
in 12-well plates at a densily of 3.5 x 104 cells per well for H9C2 myoblasts and 
-7 x 10' cells per well for CV-l fibroblasts and HepG2 hcpatocytes. respectively. 
H9C2 myoblasts and CV-1 fibroblasts were maintained In DMEM (Highveld 
Biological , South Africa) supplemented with 10% fetal calf serum (v/v) and 100 
Ilg/ml of penicillin/streptomycin. HcpG2 hepatocytes were maintained In Ear1e's 
Base Minimum Eagle's Medium (EMEM) (Highveld Biological, South Africa) 
supplemented with 10% fetal cal f serum (v/v) without penicillin/streptomycin. All 
cells were Incubated at 37"C (95% humidity. 5% C~). 
c) Transfection studies 
The cell transfection studies were carried out using FuGENE 6 Transfecl ion 
Reagent (Roche, Mannheim, Gennany) following tile manufacturer's manual. 
Briefly, twenty lour hours following plating. neonatal cardiomyocytes, H9C2, CV·l 
and HepG2 cells were tranSiently translacted IOf 48 hoors with 0 .38. 0.2. 0.6 and 
0.5 ~g. respectIVely. of the fua.length pPII~ 1317 human ACC~ promOIer-reporter 
luclferase construe! (ACC~ plasmid ONA) and 10 ng 01 pRL CMV-Renliia was 
added 10 correct for transfectlOfl effiCiency. FuGENE 6 transtectlon reagent was 
diluted in serum-free medium and added to the ACC~ plasmKl DNA. A FuGENE 
6:DNA complex was allowed to form by gently mixlI"Ig and inCUbation fOf 15 
minutes at room temperature. FollOWing incuballon. the FuGENE6:DNA complex 
was carefully added (drop-wise) into the wells containing medium. Forty eight 
hours afler transfeclion. cells were subsequently harvested by washing tWICE! with 
cold IX PBS. lysed by adding 100 III of IX PasSive Lysis Buffer (pLB){Promega. 
Madison. WI). The Iysates were centrifuged In a mlcrofuge at 12.000 rpm for 2 
minutes at 4C, The supernatant was stored at -80"C for subsequent 
measuremoot of lucilefase activities. 
For cotransfectlOn stlKlies, fuH-Iength pPII~-1317 human ACC~ promoter-reporter 
IUClferase construct was transfeeted together With 0.19, 0,8. 0,3 and 0.251lg of 
the USF1-pUC-SRu expression (generously provided by Dr. Tetsuya Kamalakl. 
HoIIkaldo University. Japan) f()l" neonatal cardiomyocytes. H9C2. CV-l and 
HepG2 cells. respectively In addliional experiments. promoter deletion 
construe!s pPH~569J-+-65. pPII~m5691-+-65 , pPIlp..3491+65. pPlI~-93/+65 , pPII~· 
38/+65 and pPIlp..I6/-+-S5 wefe translected as earlier described (deletion 
constructs sllown In Figure I) The serial deletion human ACC~ promoter-
reporter Iuclferase constructs have been prevIOusly describe!fO& and were kindly 
ptovlded by Dr. K-S Kim (Yonsei University College of Medicine. Seoul, Korea). 
Transfection studies also Indueled 0.38 [Jg of the USFI reponm construct 
(pUSF l-luc) (Panomlcs. Redwood City. CAl containing mUl tiple copies of USF1-
speollc enhancer elements in order to provide a measure of endogenous USFI 
transcriptional adivity in cardiomyocytes. H9C2 myoblasts .md CV-l fibroblasts. 
To determine luoferase adwity. the dual IUClferase reporter-assay system was 
used according 10 the mall\Jfacturer's instructions (Promega. Madison. WI). Total 
DNA concentrations were equalized With pGl3-Basic (vector only). Results are 
expressed as relative luofef"ase units nO!1'1'lalized to the activity of pGl3-Basic for 
ACCp, promoier-reporter luciferase construct and pControl-luc for USFI reporter 
vector (ve<:t(l( only = 1). These dala represent the mean ± SEM of 2 or more 
Independent experiments performed in triplicates. To further assess the 
mechaniSmS responsible for tile USFI-medlated indudion of ACCi3 promoter 
activity. we performed vanous treatments For the low versus high glucose 
expenments. cells were plated In charcoal-stripped fetal calf serum (sFCS) 10 
avoid possible Interference 01 growth factors With the glucose response. Twenty 
four hours after transfecllon. cells were washed twice wilt! phosphate-buffered 
saline followed by an exposure to either low (5.5 mM) or high glucose (25 mM) 
fur <:III , ... kllhuroal 24 louur». 2·o..u~~1JUJSe (25 rllM) W .. S i"J.Jt!d Iu t; .. lIs for 24 
hours under high glurose (25 mM) COnditionS. For the okadaic acid eltP9rimenls, 
cells were treated (48 hours after transfecllOn) with 50 nM, 75 nM and 100 nM 
okadaiC acid (Slgma-Aldlich. Germany) for 6 hours I" a separate experiment. 
cells were If'Icubated With 1 mM and 1 5 mM oxythlamlne (Slgma-Aldrrch. 
Germany) fOI twenty four hours 
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Figure 1. Schematic representation o f human Aeep promoter II (pPUP-1317) 
ser ial deletion reporter constructs. 
(A) Full .length pPIIP-1317/~65, With E-boxes 1-4 (eANNTG) E-box mutants were 
generated for E-bo~es t·3 by " te-drrec:.ed mutagenesiS subsbtutlng TG With AA In each 
CANNTG (dellOted by astens~ ) (B) PPIIIl-5691'65 With E-boxes 1-4 (Wild-type) (e) 
pPllp-m569/+65 With mutated E-boxes '-3 and IDtati E-box 4 (mE t*E2.E3) (0) pPII~ 
3491+65 With E-box 4 only (E) PPIl3-IB/·65, With E-box 4 only 
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2.2.3. Stalislical analys is 
These data are e!(pressed as mean 1: SEM The mRNA and peptide levels arc 
reported in arbitrary umts (AU) deternHned by dcnsrtornotry and normalized to 
controls (mean control value is set 10 100) Tho unpaired Student's t test was 
l lscd to determine differences between two groups ANOVA one-way analysis of 
variance was used to delemlloo SIgfllficance bel\veen control and experimental 
groups whero more Than two sample populahons were compared. All post·hoc 
delcrmillat iolls (when ANOVA showed Siglllficant differences) were made by the 
BonferronileSI Vailies were conSidered significant when p<O 05. 
2.3. Results 
2.3.1. Induction of in 111110 ACCP gene and protein expression in response 
to elellated glucose levels 
To investigate our hypothesIs that ACCP gene expression Is glucose-responsille 
in the heart. mice were fasted and re-fed a high carbohydrate diel (RHC) for 48 
hours. Circulating plasma gtucose levels and ACCP gene and protein expression 
were thereafter determined. Plasma glucose levels were significantly elevated 
from 6.6 ± 0.2 to 10.3 ± 1.6 mmoVL (p<O.O I vs. control. n2:6) in the RHC group 
(Figure 2AI. 
In parallel. ACCP steady-state gene (n2:5, p<OOOl lIS. control) and protein (n:5. 
p<O.OOl liS. control) expression were significanlly elellated follOWing high 
carbohydrate re-feeding (Figures 26 & 2C). These data suggest that the 
induction of ACCP gene expression In the mouse heart is associated with 
elevated systemic glucose lellels. 
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Figure 2A. Elevated glucose levels following high carbohydrate refeading. 
Blood was collected by cardiac puncture and plasma glucose levels measured in fe-fed 
high carbohydrate (RHC) dlel and C()(1lrol mtce Data are repre5ented as means ± SEM 
(n:&) The aSlens.k denotes a s;gn~icant difference betweel1 RHC aod control mice, 
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Figure 2B. Induction 01 in vivo ACCP gene expression in response to 
elevated g lucose levels. Cardiac ACC~ mRNA 1eV('ls In response to a mlee! hIgh 
carbohydrate IRHC) diet Inset - represenlahve Northem blot I~ shown for ACCp 
Ethidoum btomode stained 28 S tRNA IS mcluded 10 demonstrate unchanged RNA 
e;.cpresslon DenSltometric analysis of Northern blots was performed and data 
normalized to 28 S rRNA (mean connol value set ill 1(0) The bars represent mean t 
SEM (nc.5), The astensk denotes a s'9n11tcan1 difference be~n RHC and control lnlce, 
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FIgure 2C. Induc tion of in vivo ACCP protein e:.:pression In response to 
elevated g lucose levels. ACCj3 protein (280 kOa) levels In response to RHC Bar 
graphs represerrt the mean cardiac acetyl-CoA cartxJxylase (ACCPI peptide levels IOf 
RHC and control mice normalIZed to Ponceau-stained protem bands (mean control value 
set al 100) (11"'5) The astensk deootes a signfficanl dtfference between RHC and conl rol 
mI~, "p<O 001 Inset - A representatIVe Western blol for ACCP Poncew.stalned bands 
ill!! shown 10 indicate unchanged protem loading AU - arbUiII)' units 
2.3.2. Glucose induces human ACC~ promoter activity 
To further elucidate the role of glucose in the induction of ACC~ gene 
e.-pressIOn. we began by transiently transfecting a 1.317 bp human ACC~ 
promoter·luclferase construct ( pPII~-13171+65) Into neonatal cardlomyocytes. 
H9C2 myoblasts. CV-l fibroblasts and HepG2 hepatocytes. Twenty four hours 
after transfection. cells were exposed to ellher low (5.5 mM) or high glucose (25 
mM) for an additional 24 hours. High glucose exposure resulted in a moderate 
but non-Significant increase In ACCI3 promoter activity in neonatal 
cardiomyocytes and CV-l fibroblasts Moreover, high glucose exposure 
significantly elevated ACCI3 promoter adivlty from 1.87 ± 0.26 to 3.91 :!; 0.37 
(n=9. p<O.OOl) and 1.4 ± 0.2 to 3.5 ± 0.2 fold (n=3) in H9C2 myoblasts and 
HepG2 hepatocytes. respectively (Figure 3). In agreement with our gene and 
protem expression data , these analys~ demonstrate that the human ACCI3 
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Figure 3, ACe/! promoter lucilerase activity in response to low/high 
glucose levels. CardlOmyocytes. H9C2 myobla$ls, CV-l fibroblasts and HepG2 
hepal(K;;ytes were transtenlty COIransledecl WIth the Iull-length ACCI3 promoler-reporter 
construct (pPII13-13171+6Sj Cells were exposed to low (55 mM) Of t.gh glU(:ose (25 
mM) leYeis lor an additional 2<1 hours Results are expressed as relative lud!erase unrts 
normaliled to the achvlly of vector only (pGL3-BasH; = 1). These data represent mean :t: 
SEM of 2 or more Independent expenments performed In tnplicates. unless staled. 
H&pG2. nl., Independent experiment. "p<O 05 vs pPl113-13171+65 (low glucose) 
2.3.3. USF1 transactivates ACC ~ promoter activity 
To delineate transcnpbonai pathways mediating glucose-induced ACC~ 
promoter actiVity. we next performed transfectlOn asS<lYS employing an 
expression vector 01 USF1 , a cand~ate glucose-re5pOflswe transcription factor. 
Recently, four E·boK consensus sequences have been identified on Ihe 1,317 bp 
human ACC~ promote~ i.e. E-box 1, E-box 2 and E-box 3 located further 
upslream 01 Ihe transcripIJon start site (-569 to -348) and E-box 4 located 
immediately adjacent to It (-14 to -9) (Figure 1) Since high glucose eKposure 
failed to increase ACC~ promoter activity in neonatal cardiomyocytes and CV-l 
fibroblasts. we first tested whether USFI would Induce ACC~ promoter activity 
under low glucose, Secondly. we tested whether high glucose eKposure would 
further Increase USF1-medlated ACC~ promoter actiVity In neonatal 
cardiomyocytes, USFI overexpression Increased ACC~ promoter actJvity from 
2.75± 0.37 to 5.91 ± 0.47 -fold (n:6, p<0.05) and 3.23 ± O.38 to 4.66 :r 0.35 -fold 
(n=6, p<0.05) under low and high glucose exposure, respectively, (Figure 4A). In 
CV-l cells, USFI markedly increased ACC~ promoter activity by 19.2 t 1.33-
fold (n:15. p<O.OOI ). under low glucose exposure. A further USF1-medialed 
increase of ACC~ promoter actiVity was observed WIth high glucose eKposure 
(p<O.OI vs. USFI + high glucose) (Figure 49). However. USFI overexpression 
failed 10 increase ACCj3 promoter actIVity in H9C2 myoblasts whereas mducbon 
01 the ACCj3 promoter activity was noted in HepG2 hepatocytes (n"3) (Figure 
4C). Collectively, these data suggest that USF11ransactJvates the human ACC~ 
promoter activity in a cell type-SpecifIC manner and further Implicate the 
" 
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FIgure 4A and 48. USF1 transactlvates human ACCP promoter activity. A} 
Cardiomyoc:ytes and B) CV.\ fibroblast!! were tranSIently cOlranslected wrth the fun .. 
length ACCjl piomoler·reporter construct (pf'1I~13\71+65) and USFI expression vector. 
After 24 hours. cell!! Wflfe exposed to low (5 5 rM1) or hlgh glucose (25 mM) levels lor an 
addibonal 24 hours Results ate expressed as retatIVe tucllerase Units normalized to the 
activity of vector only (pGL3-BaSlC=I) These data represent mean:t SEM 012 or more 
Independent expenments peflormed In triplicates 'p<O 001 vs pPII~1317/+65. 'p<O 01 
vs pPUjl-1317/+65 + USFI (low glucose) 
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Figu re 4C. USF1 transactivates human ACCP promoter activity In a celt 
t ype-specific manner. H9C2 myoblasts arod HepG2 hepatocyte5 were transiently 
cotranslected WIth the full-length ACCI3 promoter-reporter construct (-1311/+65) and 
USFI e~pression vector Cells were e~posed to high glucose (25 mM) levels for 24 
hours Results are expressed as relahve lUCIle rase units normalIZed to the actilllty of 
vector only (pGL3-Basic " 1). These data represent mean ± SEM 01 2-5 Independent 
e~periments performed in triplicates, unless stated. HepG2, n"3 or 1 Independent 
experiment 
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2.3.4. Oelineation of the transcriptional machinery pathways directing 
human ACCIl promoter activity 
a) 2-0coxyglucose (2-0G) inhibits human ACCI1 promoter activity 
Previous studies have shown that xyluI0se-5-phosphate. an intermediate in 
pentose phosphate pathway (PPP), increases transcription of glucose-
responsive genes via stimulation of PP2A. 'O. 11. 13 To investigate the 
transcriptional mechanisms directing USF1-mec!lated ACCIl promoter activity, we 
reasoned Ihat inhibition of the PPP pathway should result in a reduction of USF1-
mediated transactivation of ACCIl promoter activity. To accomplish this, we used 
two pharmacological compounds known to inhibit the PPP pathway i.e. 2-
deoxyglucose and oxylhiamine. 2-Deoxyglucose (2-DG). a nonmetabolizable 
glucose analogue. has previously been used as a glucose deprivation mimeti<! 'e.. 
219 and has been shown to Inhibit G-6-PD activity, a critical step in Ihe PPP 
pathway. In the liver and skeletal musde of ra15.m Furthermore. 2-DG 
administration in HeLa cells strongly Inhibited the activity of Spl, another 
glucose-responsive transcription faclor.22IJ To test our hypothesis, we treated 
neonatal cardiomyocytes and CV-l fibroblasts with 25 mM 2-DG for 24 hours. In 
neonatal cardlomyocytes, 2-DG did not inhibit USF1-mdu1;ed ACCI3 promoter 
activity (Figure SA). However. in CV·l cells. USF1·induced ACCIl promoter 
activity was strongly suppressed in the presence of 2-DG (p<OOI vs. ACCIl ... 
USF1) (Figure 58). Moreover. oxythlamine, a Iranskelolase inhibiIOf,221. 222 did 
nol have any effect on USFt-mduced ACCI3 promoter activity in both cell lines 
employed (Flgums SA and B) These data Implicate the Hwolvcmenl of glucose 
and lis metabolite, x·s·p In the transcnptlonal regulat ion of the ACCI3 promoter If1 
CV· I cells 
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Figure 5. The effect of 2-deoxyglucose on USF1-induced activation 01 the 
human ACCj3 promoter activity. (A) Cardlomyocytes and (8) CV-' cells were 
transiently cotransfecled WIth the ful l-length ACCP promoter-reporter Coosiruct (pPIIP_ 
1317/+65) and USFt expressioo vector under high glucose (25 mM) conditions. The 
follOWing day, cells were exposed to 25mM 2-deox)'9luco5e for 24 hours Resll~s are 
expressed as relative luc~erase UnitS normalized to the actiVity of vector only (pGL3-
Basic=1) These data represent mean ± SEM of 2 Independent expenme!1ts performed 
In triplicates 'p<O,Q5 V5. pPIII3-13171+65, 'p<O 001 VS PPIlp..13171+65 +- USFt 
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Figure 6. The effect of oxythiamine on human ACel} promoter activity. 
(AI CardKlfflyocytes and (S) CV- \ fIbroblasts were tranSiently COlransfecled WIth lull-
length ACC~ promoter and USFI express,on veClor Tl1e folloWIng day. ceDs were 
treated Wltn the ,ndlCated eoncentrat.ons of oxylhlamine for 24 hour5. Results ,lie 
eXp1"essed as ,e/awe luclferase units llOnl'ahzed 10 the acbvlty 01 vector only (pOLl-
Basic" 1) These dalil represent mean 1 SEM of 2 tOdependenl e~penments perlonned 
In Ulp~cate5. 'p<O 05 '15 pplI~13 1 7/'"6S 
b) Inhibition of PP2A reduces human ACCI} promoter activity 
Protein phosphatase 2A (PP2A). a downstream target of X-5-P. has been 
implicated in increased gene transcription by promotilg translocation of 
carbohydrate response element binding protein (ChREBP) Into the nucteus 
wtlere It btnds to the promoter region 01 target genes 10. II. 13 tn this study. I 
Investigated whether PP2A phospho~ates and activates USFI to subsequently 
promote ACCI3 transcriptional activation. I therefore proposed thai inhibition of 
PP2A would reduce USF1-mediated ACCI! promoter activity. Okadaic acid. a 
PP2A Inhibitor, was used to confirm whether X-5-P mediated transcriptional 
InhibitIOn 01 USFt-lnduced ACCIl prom<xer actIVIty involved actIVation of PP2A. 
In lIlis study, I found lIlal okadaic acid suppressed USF1-mduced ACCI3 
promoter activity in a doslHlependent manner in neonatal cardlomyocytes and 
CV- ! cells (Figures 7A and B), These data confirmed the involvement of PP2A In 
the USF! -medialed uaoscnpllonal regu1ation 01 ACCI3 promoter 
63 
A. ,. 
.~ •• , " • ••• • ,
• ,. 0 •• , " • ,. > 
0 
" , • ,.. " • 
B. 18.(1 
~ 16.0 , \4.0 
• 12.0 • 
~ 10.0 , •• " • •• 
~ •• 











o 50 nM Okadaic acid 
~ 75 nM Okadaic acid 
o 100 nM Okadai/: acid 
Figure 7. The effect of okadalc acid on human ACCP promoter activity. 
The full_ length ACel> promoter (pPIIJ3-1317/+65) and USFI expression vector were 
transiently cot ransfected Into card,omyocytes (A) and CV-l rells (8) After 48 hours the 
ce lls were treated With okadaoc aCId for 6 hours. Resul1s are e~pressed as relat,ve 
IVCllerase uMS normalized to the act'vlty 01 vector only (pGL3·Basic=l ). These data 
represent mean i SEM of 2 or more Independent expenments performed In tnpllcates 
'p<O 05 VS. pPIIi3- 13171+65, 'p<O 05 \IS . pPIII3 -13171+65 + USFI (untreated) 
", 
2.3.5. Assessment of endogenous USF1 transcriptional activity in 
cardlomyocytes and CV-1 fibroblasts 
a) Endogenous USF1 transcriplional activity Is Independent 01 glucose 
levels. 
To determme whether endogenous acllvlty of USF1 transcripllon factor is under 
the control of glucose, we transiently transfacted neonatal cardiomyocytes I;lnd 
CV-1 fibroblasts with a USFl reporter construct (containing multiple copies of 
USF1-specific enhancer elements) under low (55 mM) and high {25 mM} 
glucose conditions. The transcriptional activity of the USF 1 reporter construct 
was significantly higher compared to control repCl1er constnJd i1 both neonatal 
cardiomyocytes and CV-l fibroblasts (p<O.OO1 VS. pControl-luc In both cell 
lines). However. exposure of the USFl reporter construct to either low or high 
glucose condUiofIs showed a Similar effect, thereby imptying that endogenous 
USFl transcriptional activity Is Independent of glucose levels (Figures SA and 8). 
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Fig ures SA and B . Endogenous USF1 t ranscript ional activity Is Independent 
of glucose levels. The USFI reporter vector (pUSF1·luc) was IraJ"lsOenny transfected 
iJ"lto cardlomyocyres (A) and CV·l cel ls (8 ) After 24 hours. cells were exposed to low 
(5.5 mM) Or high (25 mM) glucose for a further 24 hours. Results are expressed as 
relative ludferase units normallzed to the ac~vlty of vector only (pControl·Luc '" I). 
These data represent mean :t SEM of 2 independent expenments performed in 
tnplicales, ·p<O.Ol vs. pComrol·luc 
b) Endogenous USF1 transcriptional activity is inhibited by okada;c acid 
We have prevIously demonstrated tllat USF 1-mediated Induchon of ACCP 
promOier activity is Inhibited by okadaic acid (Figure 7). To further verify these 
results, we transient ly Iran~fectcd Ule USF1 reporter construct in tile presence of 
okadaic acid. a PP2A inhibitor Again, okadaic acid significantly at1enuated USF1 
transcnptionat acllvlty In a dose-dependan1 manner (p<O.05) (Figure 9). These 
data further support tile ro le of glucose lIletabolites In the transcnpllOnal 
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Figure 9. Okadalc acid suppresses endogenous USF1 transcriptional 
activi ty . The USFI reporter vector (pUSFt·Luc) was tranSJenUy Iransfected mto 
Cilrdiomyotytes (AI and CV- l cells (B) After 48 hours cells were treated with okadalc 
aCId for 6 hours arld Iud/erase act ivItIes were measured ReSIJ lts are expressed as 
le lat lvti luof,H .. litI U"I1'" "UI " 'd l ,~..u IU tto .. ~~IIYL(y ul VtlelO' only (pContpoi·Luc '" I) 
These dala represent mean 1 SEM 01 2 or more Ir'l()epenc!ent exper,ments performed in 
mphca!l!Is. unless stated 'p<O 001 vs pConlfol·Luc 'p<O 05 vs pUSF1·Luc (Ul1lrealed) 
<,' 
2.3.6. Assessment of USF1-dependent Iransactivation sites of the human 
ACCII promoter 
a) USF1 transactivation 01 the human ACCjl promoter does not occur vIa E· 
Boxes 1·3. 
Previous investigatOfS have demonstrated thaI USFI and USF2 isofonns bind E· 
box sequence mollfs (CANNTG) as homo and/or heterodimers on promoter 
regions. increasing expression of several target genes. IW Moreover. the human 
ACCI3 pl"Omote/ is transcriplJonally activated by the muscle specific factor , MyoD, 
via the E·boxesl·3 located al positions ·569 to ·348.;>0& To further investigate 
whether E·boxesl·3 are involved in USF1-induced ACCjl promoter actiVity. I 
employed two human ACCI3 pl"omOler deletion constructs i.e. PPlljl·569/+65 (with 
E-boxes 1-4) and pPllp-m569/+65 (mutations within E·box I , E·box 2 and E-box 
3) (Figure 1). Here, USFI overexpression induced ACCP promoter acuvity 
(p<0.05 vs. -569/+65). The mutations In E-boxesl-3 showed no significant 
changes for basal or USF1-lnduced ACCI3 pl"omoter activity In both cell lines 
(Figure 10). These data indicate that E·boxes 1·3 are not Involved In the basal or 
USF1-induced ACCI3 promoter activity, thereby raising the posslbltity that E·box 
4 (- 14 10 ·9) andiOf an Identified region on the promoter may playa signifICant 
rote in the Induction of ACCII promoter activity 
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Figure 10. USF1 tra nsactlvation of the human ACCIl promoler does not 
occur via E- boxes1 ·3. Cardiomyocytes (A) and CV-l cells (6) were transiently 
catransfected with either the wild-type (pPII~569!+65) Of E·OOx mUlant reporter 
construct (pPIIJ)-m5691+65) (refer:o Figure 1). together WIth a USFt expression vedar 
under high glucose (25 mM) conditions for 48 hours. Results are expressed as relative 
luciferase units normalized to the 3CIM!Y of ~ector only (pGLJ..6asic"'I). These data 
represent mean ± SEM of 2 or more independent experiments perfol111ed In triplicates. 
·p.:Q,QS VS. pPII~569J+65 only or pPIII3-mS691+65 only 
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b) Assessment of USF1-<1ependcnt transactlvallon region of the human 
ACCIJ promoter using serial doletlon constructs 
To identify USF1-responsive regions within lhe human ACCIJ promoter, serial 
deleboo constructs (Figure I ) were lTanslenlly cotransfected with the USFI 
eKpresslOn vectOf In neonatal cardiomyocytes, USFI overexpression lett to a 6-
fold Induction of basal promoter activity of deletion constructs pPlI~1317 and 
pPIIP-569 (p<0.05 vs ACCIJ basal promoter activity) while basal promoter 
activity of deletion construct pPI1r.-931+65 was moderately Increased to 8.6-fold. 
suggesting the presence of a repressor site between -569 and -94 region. On the 
other hand, deletion of reQlon -92 to -39 resulted in about 50% loss of both basal 
promoter actiVity and USFt responSIVeness, suggestmg that endogenous 
activators and/or USF 1 may billd to this region thereby increasing ACCp 
promoter actiVity. A further loss of basal promoter activity (-50%) was observed 
with deletion construct pPIIP-I8I+65 but USFI responsiveness was simHar to that 
of pPUP-38J+65 (FIgure I tA). 
In CV· l cells. USFI responsiveness was Similar for deletion constructs pPIlji-
1317, pPtlji-569 and pPUr.-93 (p<O 05 vs. ACCIJ basal promoter activity). Again. 
deletion of region -92 to -39 resulted In a slglllficant reduction of USFI 
responSiveness. In addition, deletion constructs pPIlP-38 and pPII~18 had a 
slm~ar response to USFI overe)q)ression (FIgure lIB)_ These data Indicate that 
reglOll ·9210 ·39 could be a poSSIble larget for USFI responsiveness. Moreover, 
USFI responsiveness was not completely lost with deletion of regIOn ·92 10 -39, 
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Figure 11. Assessment of USF1-dependcnt transactlvatlon of the human 
ACCP promoter using serial dctetion co nstructs. Senal dele\Joo construds of 
the human ACC~ promotel were transIently cotransiected Wllh the USFI exprC$$lOn 
VectOI mto cardlomyocytH (A) and CV-l eels (8) lor 48 hotn Resuks are exprHsed 
as relallve luc,feraH UIlits nOlmalazed to the actiVIty of vector only (pGL3-8aslc 'II 1) 
These dala represent mt!an :!: SEM of 2 Of more ,ndependent expenments performed In 
Il1pllcates ' p<O OS vs ACC~ basal actIVIty 
2.4. Discussion 
The purpose of this study was 10 invesllgate transcnptional mechamsms direcllllg 
glucose-mediated ACCP gene expression Here. we show an induction of in vivo 
cardiac ACCp gene and protein expression If) mice fe-fed a high carbohydrate 
diet aftel an acute fast To further Invesllgate the association between 
augmented glucose levels and IIlcreased ACCp gene expresSion. we transiently 
transfected neonatal cardlomyocytes. H9C2. CV-l and HepG2 cells With a lull-
length human ACCP promoter-Iuci/erase construct under low or high glucose 
exposure. In agreement With our in VIVO expression data. transfection studies 
show Increased human ACCP promoter actiVity in cardiac-denved H9C2 
myoblasts and HepG2 hepatocytes In response to elevated glucose levets. 
However. no glucose-me(liated increase In ACCP promoter activity response was 
observed In neonatal cardiomyocytes_ To delineate transcrlpilonal mechanisms 
directing ACCp gene tranSCription. we performed cotranslecilon studies 
employmg human ACCj3 promoter deletion constructs and a USFI 
overexpresslon vector Under high glucose conditIOns. USFI overexpresslon 
further Increased human ACCP promot(!r actiVity in neonatal cardiOffiyocyl(!S. 
CV-' and HepG2 cells. However. USFI oVefeXpreSSKln did not have any eHect 
on ACCP promoter activity In H9C2 cells Our data therefore show that USF1 -
mediated mductiOn of the human ACCP promoter activity occurs In a cell type-
specific manner. 
-, .. 
2.4.1 Glucosf! acts as a signaling moleCUle regulati ng the human ACCII 
promotei'" 
TIle role of metabolic fuels acting as Signaling molecules regulating expressIOn of 
numerous metabolic enzyme-encoding genes hilVe recently been highlighted." 
~I For example, It has been demonstrated that the FA-responSive transcripllonal 
regulator, peroxisome prol iferalor-actlvated receptor a (PPARa). activates 
numerous FA enzyme-encoding genes In the heart:' On the other hand. 
glucose-responSive Ir<Jnscnplional mooul<Jtors for e.g Spl. SREBP I . and USFs 
have been impliC<lted in the expression of several lipogenic enzyme-encoding 
genes II ., I~" ,", However, It IS unclear whether glucose-sensing transcriptional 
mech<Jmsms regulate expression of metabolic enzyme-encoding genes in the 
heart Here, we demonstrate elevated in vivo murine cardiac ACCI3 gene and 
protein expresSion associated With increased plaSina glucose levels. In support. 
01, et al.'CI reported Increased ACCI3 gene expression following high 
carbohydrate refeedll1g in the liver To furtl,er corroborate these IlI1dlngs. we 
performed several transfection assays. Out transfectlon studies show increased 
aClivity of the full-length human ACCI3 promoter In H9C2 myoblasls and HepG2 
hepatocytes In response 10 high gtucose exposure. Our findings are consistent 
with Widmer et al ,", who reponed elevated ACCI3 protein expression in Hol liE 
hepatoma celts follOWing exposure 10 glucose However, no signlfiC<l"i! increase 
of the full-length ACCI3 promoler activity was observed in neol1alal 
cardlomyocytes and CV-t fibroblasts in response to high glucose levels 
, , 
2.4.2. USFl medialos Iransactivalion of Ihe human ACC!} gono promolQr 
USFs ure ubiquitously e~pressed and have been shown to regulate the 
transcriptlOo of sever<ll met<lbohc enzym6-eocoding genes. '? W<lng elal.m 
found USFl ptolelll levels are markedly Increased In the liver of rats re-fed a high 
carbohydrate diet followmg an acute fast Moreover, USFI null mice displayed a 
reduction of the glucose· mediated Induction of the liver-type pyruvate kinase and 
514 genes. 'SO We ne~t performed cotransfectlon studies WIth a USFI 
overexpressing vector 10 determine whelher USF 1 mediates the induclion of 
ACC!} gene promOler actIVIty in response 10 gtllCOse nux. Here, we show Ihal 
USFI overexpresslon sIQn,ficanlly elevales human ACCi3 promoler acllvlty in 
neonatal cardiomyocytes, CV·l fibroblasts and HepGZ hepatocytes. We also 
found thai hig! glucose exposure further Increased USF1-medlated ACC!} 
promoter activatIOn in CV·l fibroblasts In suppor!, glucose-responSive 
transcription factors such as SREBPI and Spl have been shown to drive 
IratlScnplional actlval ion of human ACC!} promoter In HepG2 hepalocytes. '~ 
Our data therefore ihow thaI the glucose_depenrlent :tr.llvatlOn 01 lISF! ('.;m 
induce ACC!} gene promoter actIVIty 10 a cell type-specifIC manner However, 
based on the experiments perfOfTTled. the USFI response In neonatal 
cardiomyocyles appears to be glucose-independe11. This does nol, howevef, 
rule Qui a glucose-dnven tranSCliplional program lor ACCi3 gene upregulatlOfl. 
The possibility eXIsts that different data may have been generated usmg adult 
cardlomyocyles IIlstead of neonatal myocytes. since these ceils are expected to 
exhibit different metabolic profiles Also, downstream peotose phospha1e 
pathway (PPP) or HBP glucose metobolites could perhaps mediate such 0 
response. These possibilities reqUIre further Investigations, Future studies are 
also required to test our fillchngs in vivo SlOce other invesllgators have indicated 
that USFs are 001 responsive to dietary changes. 
USFI oVOfexpresslOO did not IndUce full-length human ACCp promoter activity in 
H9C2 myoblasls, suggestlOg that glucose-induced ACCP promoter achvity may 
occur through USF1-lOdependent transcriptional mechanisms. However, il has 
previously been shown that muscle-type transcription factors for e.g. Myc and 
MyoO bind to E·boxes of human ACCP promoter thereby resultlOg In Its 
activatiQll .208 Since these muscle-type factors are abundant III cardiao-denved 
H9C2 myoblasls, endogenous ACCp gene promoler actIVation could mask 
potential USFltranscripliooal effects. 
2.4.3. Delineation of regulatory pathways directing ACCp promoter activity 
To furthOf delineate the signaling pathway(s) for glucose-induced tmnsactiva\loo 
of the human ACCP promoter, we tested the hypothesis thai metabolites of the 
PPP regula te transcription of gtucose-responsive genes via xylulose-5-
phosphatelPP2A mechanism Previous studies have shO'Nll that 2-00 directly 
Inhibits G-6-PD, a Cl1tical step in the production of downstream intermediates 
such as ributose-5-phosphate and X·5-P. HoweVOf. we found I1lat 2-DG did not 
inhibit USF I-mediated human ACCP promoter activity In myocytes. This may be 
due to the PPP being less actIVe in muscle and hlQhly active in lipogenic tissue 
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such as adipose Since it Is involved in the reductive SynthesiS of FAs from acetyl-
CoA.s In contrast, 2·OG admirnstrallOn robustly Inhibited the USF1-mediated 
human ACCJ3 promoter activity In CV·l fibroblasts. These findings slrongly 
Sl.4'port the involvcmenl of the downstream PPP Inlormediale X·S·P in the USF1-
medl3led transcriptional achvallon of ACCJ3 in CV-l fibroblasts These data also 
confirm earlier findings that the PPP regulates transcriphon In a coli Iypa-specific 
manner. O)(ythiamine. a tr.Jnsketoiase Inhlbl1or, did not significantly inlluence the 
USF1-mediated human ACCJ3 promoter activity In bolh neonatal cardlomyocytes 
and CV- t fibroblasts. Since transketolase calatyzes \tie breakdown of X-5-P, its 
Inhibition may not result in the reduchon of X·5-P mediated gene lTanSCliplion. 
Moreover, o)(ythiamlne Inhibits about 70% of transkelolase activity aod only 15% 
01 G-6-PD actiVlly Dj 
To further strengthen these findings, we lesled whether PP2A, a downstream 
largel of X-5-P Is also involved in the USFI mediated transcriptional 3diva1lon of 
human ACCJ3 promoter Here. we administered okadaic acid , a PP2A IOhlbltor 
logether with USFI cotransfedions. PP2A inhibitiorl resulted in Ihe reduction of 
USF1-mediated human ACCJ3 promoler activity in both neona1al cardlomyocytes 
and CV-t rlbroblasts In addllion, okadaic acid reduced USFI transcrlpllonal 
activity In a dose-dependenl manner CoIlecUv~y, these dala Impllcale the 
Involvement 01 a )(y!ulose.S-phosphatefPP2A mediated signal'"9 pathway that 
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Figure 12. Proposed pathway for USF1-mediatcd ACCII gene regulation 
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2.4.4. Assessment 01 USFI responsive region{s) on lhe human ACCP 
promoter 
USFs are UblqlMtously O)lpressed and haY(! been shown to bind consensus E-bo)l 
elements located WIthin the promoter regions of several metaboliC enzyme-
encoding genes. " Also. MOOfe eI al.115 demonstrated that USF·medialed 
regulation 01 the musclc--type CPT! lsolorm was abolished when E-bo)l elements 
were mulaled Since foor E-bol< sequence elements were previously Identified 
on Ille human ACCP gene pl'emoler.101I we hypothesized that USF1 -induced ACC 
promoler activity is mediated via the E·bo)les, CotransfecllOn With a mutated E· 
bo)l construct (E-bo~es 1·3) did nOl diminish human ACCP promotOf actiVity in 
both neonatal cardlomyocytes and CV-l fibroblasls. suggesllng that the 
observed USF1-medlaled mdOCllon at ACCI3 premotOf actiVity may occur via E-
bO)l 4 or another identified region on the promoter. To identify USFI-responslve 
regions Within the human ACCP premoter seflal delel!on constructs were 
transiently co transfected with the USFI e)lpression vector. In bOlh neonatal 
cardiomyocyles and CV-I fibroblasts deletion 01 region -92 to -39 resulted In -
50% loss of USF 1 responsiveness. Furthermore, USF 1 failed to induce the 
promote activity of the pPHI3-38/+65 deletion construct These data suggest that 
region -92 to -38 may be a target for USF 1 responsiveness. Our data is 
conSIstent With preVIOus stud,es1O' demOflsfrallng that glucose-responsive 
lranSCflplion factors. SREBPI and Spl stimulate Ihe transactlvation of the ACCp 
promoter via an Spl-bindlng si te and 11'0'0 sterol regulatory elements located in 
regiOns -71 to -66 and -62 to -44 respectively It has previously been proposed 
~ll 
that USFs funelion In a cell type-spe<;iflC mar.ler. !hrough different ratIOs 01 USFt 
Sfld USF2 homo- and! or heterodimers. or by Iflterac;tlOll With celt type-specifIC 
transcriptlOO cofaclors.m 22fi Therefore. we cannot exclude USFI interaction With 
other transcription ladors for e.g Spl or SREBPI known to also bind to th is 
promoter region. Coltechvely. our deletion analyses show that USF1-lnduced 
human ACCP promoter aellvlty Is mediated in a celt type-specific manner through 
region ·92 to ·39 andlor E-box 4 (-14 to -9) elements located in the first 569 bp 
upstream 01 the transcription star! si te. However, addi tional ONA binding studies 
afe reqUired to determine the exact contributions 01 Individual E-bo){ elements 
located on the humsr) ACCP promoter in the different cell lines investigated. 
These data also suggest that the glucose-fatty acid cyde may be regulated at a 
transcriptional level . since one would expect that glucose-induced ACCjl gene 
expression should result in increased malonyl-GoA levels, thereby Inhibiting 
CPTI and mitochondrial FAO (Figure 13). II has previously been shOWll that 
USFs inhlbilthe PPARy coactivator 1 ( PGC1~ependeflllransactivation 01 the 
muscle-type CPT! promoter in neonatal cardlomyocytes_~ Also, a recent study 
demonstrated that elevated glucose levels resulted in a reduction of PPARo 
mRNA levels and some of Its target genes in pallO'eatic Is!ets.m These findings 
may therefore have an Important bearing on !he pathogenesis 01 cardiac disease, 
particularly when glucose utilization is Impaired lor e g with type 2 diabetes. 
Abu-Elheiga et al.!90 demonstrated that ACCP nult mice. unlike wlldtype controls. 
did nol develop diabetes when fed an obesiTy-Inducing dlel. Moreover. Debard 
so 
et ai m reported Increased ACCP gene expression In Type 2 diabetic patients 
Therefore, glucose-mediated induction of ACCp gene expression together with 
9f1hanced FA uptake by the diabetiC heart may result in Intracellular lipid 
accumulation and detnmental tipotoxlc effects. including apoptosis and eventUally 
contractile dysfunction.:m· 22!1 This study highlights the importance of investigating 
transcriptional mechanisms directing ACCP gene expression in the heart. since 
th is may eventually lead to the development of novel ACC~ inhibitors. thereby 






Figure 13. Proposed mechanisms through which USF1-rnediatcd activation 
may attenuate fatt y acid oxidation 
2.4.5. Limitations and future d irections 
H9C2 cells are widely used as a model for cardiomyocylGs to advanCEI our 
kno~edge of molecular and biochemical mechanisms 01 the heart. 10 1 201". 10&. 2(;f 
;-(;5. 266 This ceU hne exhibits diflerent morphological characteristics to neonatal 
cardiomyocytes but preserve hormonal and electrical properties found in adult 
cardiac cells.~ 265 Despite the use of H9C2 cells to study various aspects of 
heart function, this cell line differs from neonatal cardiomyocytes in several 
respects In the first Instance, the H9C2 cell Une is a heterogeneous mixture of 
cells/'6~ whereas cardlomyocyles are a homogeneous collecl ion of heart cells. 
Thus. like the intad heart, H9C2 cells consist of various cell types lor e.g. 
cardlomyocytes, fibroblasts. and endothelial cells. The transfection studies on 
neonatal cardiomyocytes only examined the response of a single cell type. razing 
the possibility Ihat other cardiac cell types may in fact mediate the ACCI3 
response. Further transfectlon studies are needed to investigate this possibility. 
For instance. we are planning to do flow cytometry I FACS analysis to sort 
different heart cells I.e cardiac fibroblasts and endothelial cells. We will 
subsequently investigate whether glucose-mediated induction of ACCI3 promoter 
aclivity occurs in these cells. 
Secondly, H9C2 cells are embryonically derived whereas cardiomyocytes are 
derived from newborn rat heart tissue. Thirdly, H9C2 cells exhibit both skeletal 
and cardiac muscle features.2ti4, 765 These differences may have resulted in the 
distinct response to stimuli especially In substrate metabolism studies. For 
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example. Gilde et.al.?&8 have shown that neonatal cardiomyocytes exhibit a more 
pronounced expression of FA metabolic genes such as UCP2 and ACS 
compared 10 H9C2 cells. Moreover. Ihe well·described FA·responSive 
transCriptiOll faclor PPARo is abundant In neonatal cardiomyocytes but not 
detectable In H9C2 cel ls. lol These differences may have contributed to 
differential ACCp transCript ional act ivity observed with tow and high glucose 
exposure. 
Lastly, I did not measure endogenous ACCp gene expreSSion levels since 1 had 
difficulty With the Northern blotting techn ique at the t ime (as did the resl of our 
laboratory). This is onll of Ihe timitallons of this study since there may be a 
disconnection between the promoter actiVity and actual ACCP gene expression 
levels However, we are In Ihe process of peliormmg additional experiments 
(using real·llme quantitatIve RT ·PCR) to clarify this important issue. 
Chapter 3 
Nucfear Res piratory Factor 1 (NRF1) inhibits 
transactivation of the human gene promoter of the 
cardiac isoform of Clcetyf-CoA carboxylase (ACC(3) 
3.1. Introduction 
The rate limiting FA mltochondnal transfer enzyme. carMine palmiloyl 
transferase 1 (CPTl) plays a key role in tile regulahon of cardiac mitochondria' 
FAD Moreover. CPT1 gene regulahon is (in part ) under the control of PGClu. a 
Lranscrlpt ional master modulator However. PGCto docs not directly bind to the 
promoter regions of target genes. rather. It promotes FAD by acting as a 
transcriptional co-activator together with PPARo or NRF 1 Bolh PPARa and 
NRF1 have been associated IVith Increased gene expression of key mOdulators 
of FA uti lization. such as AMPK and cpn <2 ~3 n Upon activation by Its ligands. 
such as oleiC acid and Wy-t4.64J. PPARQ upregulates FAO-induclng genes 
such CPTt and MCAD 10 uilimalely sllmulate FAD.2l1-23J Likewise. NRF1 was 
associated with Increased gene expreSSion 01 CPTt In neonatal 
cardiomyocytes.!\' Tll€se studies therefore highlight the role 01 PPARo and NRF1 
in the transcriptional regulation of FAO metabol ic genes. 
Conversely. ACCp catalyzes the production of malonyl-CoA. a potent inhibitor of 
CPT 1. thereby actmg as an Indirect Inhibitor of FAO In non-lipogenic tissues such 
as the heart and skeletal muscle!"!o. 2lI In terms of the FA-glucose cycle. 
increased FAD rates should result In a concomitant decrease In glucose 
oxidat ion. However, i\ IS no\ clear whether this seqtlcl'ce will transpire a\ the 
transcript ional tevel i e. ~ LranSCflptional activators of FA-responsive genes like 
PPARo and NRFI will repress gene transcription of an inhibitor 01 FAO lor eg 
ACcp ~l . '81. <l')!l 
In light of this, we therefore hypothesl./:ed that PPARo and NRF l Inhibit ACqJ 
gene transcription thereby resulting In elevated FAO rates, To test Ihls 
hypothesis, r set out 10 establish till in viVO FA utllllabon mouse model by 
activation of PPARu. a well-known FA responsive transcrip tion factor. Here, I 
administered natural (olive 011) and synthetic PPARllligands (Wy-1 4,643) to mice 
and measured ACCj3 gene expression after three days 01 treatment. Moreover, I 
performed several translectlon-based studies overexpressing PPARu or NRFI in 
different cell lines and determining its effects on ACCj3 promoter activity In this 
study, we found that 1) administration of olive oil and Wy-14.643 (PPAA .. 
ligands) to mice over a period of 3 days promotes systemic FFA dearance and 
Induce ACCj3 gene expressioo in the heart However, transfection of a PPARa. 
expression vector together WIth an ACCj3 promoter construct did not have a 
direct effect on ACCj3 promoter activity. suggesting that ACCI3 is nol a PPARr( 
target gene. 2) NRFI inhibits both basal and USF1-induced ACCj3 promoter 
activity In cardiac denved ceU lines i.e. neonatal cardiomyocytes and H9C2 
myoblasts 3) NRFI induces basal ACCI3 promoter activity in non-cardiac derived 
cell lines I.e. CV-l fibroblasts and HepG2 hepatocytes. 4) NRFI inhibi ts 
endogenous USFI transcnptional actIVity in alt eelilines tested. 
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3.2. Materials and Methods 
3.2.1.ln·vivo studies 
a) An in-vivo FA utilization model by olive oil and Wy·14.643 administration 
PPARu has been prevIOUsly demonstrated to be an Important regulator of 
several FA utilizatIOn enZ~EH!ncodlng genes':' 'J and IS actIVated by 
endogeoous (oleIC acid) and synthetIC ligands (WY.14.643).ZlI.213 Based on our 
hypothesis. we therefore Investigated whether PPARa activation inhibi ts ACCI3 
gene expression in the mouse heOCl To activate PPAR". we administered olive 
oil (enriched with oleic acid), and the specific PPARa synthetic ligand, Wy.14.643 
(Blomol. Hamburg, Germany) 10 mice. The mice were divided into three separate 
groups. The control group received basal dlol (no treatment), the second group 
received basal diet and olive 011 (0.25 mlr13 and the last group received a 
combination of olive oil and WY.1 4,643 (100 mglkg), by oral gavage CN1 a daily 
basis for a conlinuous period 01 3 days as described belore.233 Olive oil also 
allowed the agonist to be readily and hOO1ogeneOJsly mixed, thereby ensuring 
less variation regarding the actual dose administered 10 each anima!. Moceover. 
olive oil has no toxic side effects thaI could be detrimental to the general well· 
being of the trealed mice. The Wy·14,643 dose used has previously been 
reported.D3 At the end of the e~periment s. tissue was collected for RNA isolation 
and Northern blot analyses as previously desaibed (chapter 2, section 2.2.1.). 
" 
b) Free fatty acids measurements 
Blood was collected by cardiac puncture from all experimental groups. Samples 
were centnfuged at 3,500 rpm for 10 min and the supernatant collected to 
detenmne plasma levels as described previously.1II Plasma FFA levels were 
speclrophotornetricaliy determined using a commen::ially available krt for free 
fatty acids (Hal f-micro test kit. Roche Mannheim. Basel. S\yjtzer1andj. 
3.2.2. In -vitro studies 
a) Transfoctlon studies 
Transfections were camed out as previously desaibed (chalXer 2, section 
2.2.2.). For this study, the fun-length PPIII1- 1317 human ACCI1 promoter-reporter 
luciferase construcro' was transfected WIth equat amounts of either 
pSG5fPPARct or NRF1-pSG5 expression vector. To assess whether USF1-
dependent activation of the ACCI1 promoter Is regula ted by NRF1 , I co-
transfected the ACCI1 promoter-reporter construct ± 0.19, 0.8, 0.3 and 0.25 ~g of 
the USF1-pUC-SR« expression vector ± NRFI expression veclor for neonatal 
cardiomyocytes, H9C2 myoblasts, CV- l fibroblasts and HepG2 hepatocytes, 
respectlvely Adcllllonal trans/actions With ACCp promoter deletion construets 
pPIII1-569/+65. pPIII1-931+65, pPIIP-38/+65 and pPllp-18/+65 together with 
NRF1-pSG5 expression vactor were also performed (deletion constructs are 
shown in chapter 2. Rgure 1 I. 
To assess whether endogenous USF 1 transcription facter transcriptional activity 
Is under the control of NRF 1, neonatal cardiomyocyles, H9C2 myoblasts and CV-
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1 fibroblasts were transiently (ransfected as previously described (chapter 2, 
section 2.2.2) i equal amounts 01 the NRF 1 expression vector, respective'Y. 
The pSG5rPPARa expression vector was generoosly provided by Dr. W. Wahll 
of the University of Lausanne, Switzerland. The NRF1-pSG5 expression vector 
was constructed by Dr. Richard Scarpulla and made available to us by Dr. Dan 
Kelly (Washington University School of Medicine, MO). 
3.3. Results 
3.3.1. The rote of PPARo in the transcriptional regulation of ACCp 
a) Activation of PPAR(t induces ACCp gene e~pression In the mouse heart 
The IIpld-aclivated transcr ipllon factor. PPARq is a pivotal transactivalor of 
several FA enzyme-encoding genes, Including epn and MCAD.42, ~l 
Fwlhermore, PPARo is activated by bOlh endogenous and synlhetic ligands such 
as oleic acid 211. 232 and Wy-14.643. respeelively In ligtl l of this. olive o~ . a 
nalural source of oleic aCid, and Wy-14643 were orallV admlnislefed 10 mice for 
3 days_ To conhrm whether our In Vlli'O mouse model promotes FA utiliZation. we 
first measured plasma FFA levels togeUlet Wllh MeAD mRNA e~pression, as 
markers of FA utlllzalJon 
Olive 011 admlnlslratlOll alone did nOI have any atfeel on plasma FFA levels. 
However. the comblnahon 01 otlve 011 and Wy-14,643 resu lled In a signifICant 
reduction In FFA levels (p<O,05 vs, conlrol mICe) (Figure 1) and mamtenance of 
glucose levels (dala not shown), Tile tfanscnpt levelS of MCAD were Increased 
by 1>0111 ullve dlll.l tile WlIllJllldholl ul ullyt! 011 dl lll Wy-14.643 (p<.O.05) (Figure 
2A) We neKI Investigated wtlelher PPARo-mediated whole-body melabollc 
changes affected ACCP gene expresSion The ac!m .. lIstralion of Olive oil resulted 
In a moderate IIlduchon of ACCI3 gene expressIOn versus control (NS) 
Surpnslngly. the comb,natlOll 01 ohve all and Wy- 14,643 further Increased ACCI3 
gene expression versus the olive all alone group in the mouse heart (p<O.05) 
(Figure 2Bj, These data suggest that actlVahon of PPAR" by olive oil and Wy-
., I 
14 643 promotes FAO thereby increasing systemIc FFA clearance However. It IS 




















Figure 1: The ellects 01 PPARo Ictivation on plasma Iree latty aCids levels_ 
8100d .,.H toIle<:ted by e.fdilC puncH .. Irld pjasma FFA levels meaSl»'ed In convol 
olIve OIIlncI oItve of • Wy-14 ~3 I, .. ted tmc:e These data are Iep'esented IS me_ 
SEM In 61 The Hl_k denotes I IIgn,ftcanl d "erenat bet .... een oIrY. 011 • Wy-- 1 •. &43 
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Figure 2A and B: Increased ACCI3 gene expression in response to in vivo 
administration of the synthetic PPAR\.I l igand, Wy_14,643. Olive 01 1 (250 
1'1) ,lndlor Wy- 14,643. a specific PPARu agonlsl, was admin istered (100 mglkgld"y)to 
mice by oral gavage for a penod 01 3 days. Contlol mice were only given the basal diet 
Inset - rep resentative Northern blot IS shown lor me<liutTl--(:h,,"n at;yl-CoA dehydrogenase 
(MeAD) and cardlac-ennched acetyl-GoA carboxy lilse (ACCjI) The bars represent mean 
t SEM (n ;,: 4) The aSlensk denotes iI SIgnificant difference between mice adm,,"stered 
Wy- 14,643 (w11I1 olive 011) versus ol ive Oil-treated animals (p < 005) AU - arb~ ra ry un,ts 
b) PPARa overeltpression does nol induce ACCIl promoler activity in 
cardiac· derived cell s 
To further investigate the concept that PPARo may Induce ACCIl gene 
expression, I Irarlsienlly co-transfected neonatBl carchomyocyles, H9C2 
myoblasts and CV-t cells wilh the full-length human ACCi3 Pfomoter-Iuciferase 
roponer construct and a PPAR" expression veclor In contrast to the in VIVO 
dala , PPARlt ovorcxpression did not have any effect on ACCp promoter actiVity 
in cardlac·dorived cells I.e. cardiomyocytes Of H9C2 m)1)blasts (Figure 3) 
However, PPARo ovorexpresslon significantly elevated ACCp promoter actIVity 
In CV-1 fibroblasts (Figure 3). Togethor, these data suggest that PPARu may 
regulate ACCP promoter actll/lty In a cetllype·spoollc manner 
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Figure 3: PPARo overexpression does not inc rease ACCP promoter activity 
in heart·deri ved cells. 
Cells were coJransfected wrth the full-length pPIIII-1 317 human ACCjI promoteHeporter 
construct together With the pSG5rPPARa expressIOn vector Cel ls were subsequently 
Cultu red for an addit ional 48 hours where alter Iysates were co llected and Iuclfe rase 
activit ies measured Results are expressed as relative luelferase urulS normalized 10 the 
actIVity of ~ector only (pGLJ-Basic '" 1), These data <I re represented as mean ± SEM 01 
2 or more independent expenmeJlts periormed In tnplicates ·p<005 vs pPIl II-1J17 
(on ly) 
3.3.2. The role of NRF1 In the transcriptional regulation of ACCP 
a) NRFl Ov(!roxprosslon Inhibi ts bilsill ACCP promoter activity In noonatal 
cardlomyocytes and H9C2 myoblasts 
NRF1 has been previously associated With gooes regulating FAD.II9· 00 However, 
since ACCj3 inhibits FAD via malonyl-CoA production. we reasoned thaI NRFl 
promotes FAD, in part. Via Inhlbrllon of ACCIl gene expresslOfl We began to test 
this hypothesis by emploYIng transleclion-based studies to <In<llyze the effect of 
NRF1 overexpfession on ACCIl promoter activi ty. As previously demonstrated, 
ACCI3 promoter actIVity WilS Induced basally for the full-length pPIIIl-1317f+65 
construct in neonalal cardlomyocytes (p<O.05 'IS. pGL3-8asic). Interestingly, 
eotransfeetion With NRF t attenuated basal ACCj3c promoter activity (p<O.05 'IS. 
pPllj3c-1317f+65) (Figure 4A) 
To confmn the transcripllonal Inhibition of ACCj3c by NRFl in the heart. we 
repeated these expenments using H9C2 rnyoblaSlS, a heart-derived cell line 
Here. ACCI3 pfomoter basal activity was s'9flifleantty induced for the pPII~ 
1317"+-65 construct (p<O.05 'IS. pGL3-Basic). Again, NRPI QVerexpression 
suppressed basal ACCj3c promoter activity (p<O.O I 'Is. pPlill- t 3 171+65) (Figure 
48) Together these data demonstr<lte that NRFl QVOfexpression Inhibits basal 
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Figu re 4A and B: NRF1 overexpression Inhibits ACCP promoter ac tlvltv In 
heart-derived cells. Cells were colranslected with the full.length PPIIIl-1311 human 
ACCIl promolef-reporter constrUCI logether With the NRF1·pSG5 expression vector 
Cell! were subsllquenUy CUltured 10/ an add~IONII 48 hool'$ where artef ~ales Wafe 
colle<:ted and luclferase actJvlties Results are e.pressed as relaltve luaIer3se UrltS 
normalized 10 the actlVlty of vedOf on~ (pGlJ.aaslc .. 1) These data afl! represemed 
as mean :Ie SEM of 2 or more lfIdependent ~perrnents performed in IrJpIica1es 'p<O 05 
vs pPllp-1317 
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b) NRF1 ovcrexpression induces basal ACC P promoter activity in CV-1 
fibroblasts and Hc pG2 hcpatocytes 
In light of these findings, we next tested whether NRFl Inhibits ACCI3 promoter 
activity in non-cardiac derived cell lines i.e. CV-1 fibroblasts and HepG2 
hepatocytes. Here. CV- ' fibroblasts were transienUy transfected with the pPlIl3· 
13171-+65 promoter construct. resulting In the Induction of basal promoter actiVity 
(p<O.05 vs. pGL3-Sasic) (Figure SA). NRFl overexpression further induced 
basal ACCI3 premoter activity for the full-length pPIl I3-1317/"'65 promoter 
construct (p<O 001 ). Of note. no basal induction of ACCI3 promoter activity was 
observed With transfection of promoter constructs Into HepG2 hepalocytes. 
However, NRFl overexpresslon also induced ACCI3 promoter activity in HepGl 
hepatocytes (p<O.Ol vs. pPII13-1317/+65) (Figure 58). These data show NRFl 
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Figure SA and B: NRF1 overel(presslon Induces basal AC CIl promoter 
actiyity in CV· ' fib roblasts and HepG2 hepatocytes. 
Cells wele cotransfected WIth the lull.length pPIIII· 1317 human ACqt promoter·reponer 
CI)/'lstnJCt together with the NRF1 ·pSG5 expression vector Cells were subsequently 
cuHured for an add~lonaJ 48 hours where alter Iysales were collected and IUClferase 
actiVities measured Results are expressed as relalille IUClferase units norrnalt/!ed to the 
aellyfty 01 veelor only (pGLJ.-Basic" 1). These data are represented as mean.t SEM of 
2 or more independent el(perJments performed In triplicates 'p<O 05 VI. pPtl)'l·1317. 
c) Assessment of putative NRF1 regulatory regions on the ACCI3 promoter 
in neonatal cardiomyocytos and H9C2 myoblasts 
As far as we are aware. there are no dassic NRF1 recognition slles located on 
the human ACCI! gene promoter. However. NRFI has been shown to regulate 
expression of genes that are devOId of NRFI recognition sites by interacting with 
myocyte enhancer factor-2 (MEF-2) and/or E-box consensus Cls-elemeots.l J4-llII 
For work relating to this thesis we did not find ACCI! promOler actiVIty 10 De 
regulated via E-boxe5 1-3 and speculated that E-box 4 and/or the -92 to -39 
regions may be responsible for indOOion of ACCI! promoter activlly (refer 10 
chapter 2. Figure 10)_ We reasoned that the inhibitory effect of NRFI may be 
mediated via interactlOl1 With E-box 4 andlor the ·92 to -39 regIOns of the human 
ACCI! gene premOlar To further pursue Ihls concept we transiently cOlranslecled 
various ACCI! promoter detetion constructs (chapter 2. Ftgure 1) WIth an NRFI 
expression vector into cardlOmyocytos and H9C2 myoblasts. 
In both caroiomyocytes and H9C2 myoblasts. cotransfection with NRFl 
overexpression attenuated basal ACCI! promoter actiVity for all deletion 
constructs (p<O.05 vs. al! deletion constructs) except for the pPU(l-181+65 
construct (Figure 6A). Together these dala demonstfate that NRFI 
overexpression potenlly Inhibits basat ACCI3 promOler activity In the heart and 
that NRFI possibly interferes with factOfS that bind in the -38 to -18 region of the 
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Figure 6 : NRF1 overexpresslon Inhibits basal ACCjJ promoter activity In 
cardiilc -derived ceUs lines. 
(A) Neonatal c.ardlOlllyocytes and (B) H9C2 myobIasts were tranSIently translected w ith 
ACCj3 p<Omotef deletion conSlfUCts \blacI< bars) and In the ~ expenmental group 
AC~ promoter deletlOll conslfucts were cOIJansfectlKl wah an NRFI expresSIOn v~lor 
(gray bars) lor 24 ~ iind lucferase adlYl,," measured R~lts are expressed liS 
relatille IUClferase lA"'as normal,~ to the actiVIty of vectOf only (pGL3·Basic" 1) These 
data are lepI't!Senled as mean % SEM of 2 or more independent e~pemnenls Pf!rlormed 
,n Inphcates ' p<O 05 'is basal ACCjJ promoter actiVIty 
lU I 
dj Assessment of putative NRFl regulatory regi ons on the ACCII promoter 
in CV·l fibroblasts and HepG2 hepatocytes 
CV-l fibroblasts were traflSlently cotransfeded with vanous ACCI) promoter 
deletion constructs together with the NRFl e)(pression vector. NRFI 
overexpresslon Induced basal ACCI) promoter achvlty fOf all delehon constructs 
(p<O.OOI ) (Figure 7A). However. in HepG2 hepatocytes NRFI overexpresslon 
Induced ACCP prcmoter adlvily only fOf the pPIlI)·1317f+65. pPllp·381+65 and 
pPIIP-18f+65 constructs (p<O Ot vs. pPIII)·1317/+65. pPllp·38/+65 and pPIII)-
18/+65) (Figure 79). NRFI overe)(presstOfl had no effed on pPII~·569/+65 and 
pPIII)-931+65 promoter adlvlly 
Collect ively, these findings implicate NRFI in the \ranscripllOflai regulation of 
ACCI) Furthermore. NRFI regulates ACCI) In a cell type-specifIC manner 
Indlcahng differential Interaction With cell type-sp6i:ific transc:riphonal cofactors 
and/or metabotic substra te preference and phySiological functions between the 
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Figure 7A and 8 : NRF1 overexpression induces basal ACCP promOter 
activ ity In non-cardiac derived ceU lines. 
tAl CV·' fibroblasts aod tB) HepG2 hepatocytes were tranSiently transfeeted WIth ACC~ 
promote!' delellOn CQI'ISb'ucts (black bars) ACC~ promoter dele~on COflSlrvcts were 41150 
cotransfeded WIth an NRFI exprKSlOll ~ectOf (gray bars) lor 24 hOlO ami IUel ferase 
actIVities measured Results are e)(pressed as relative luclferase urlils normahzed to the 
adMty of vectOf only (pGL3-Bl:Slc" 1). These data are represented ilS mean ± SEM of 
2 Of more independent eKpenmen's performed in triplicates, · p<O.OS VS. bil!lill ACCI3 
promoter actMty 
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3.3.3. NRF1 overexpression inhibits USF1-mediated induction of ACCP 
promoter activi ty 
We have previously demonstrated thai USF1, a glucose--responsive transcription 
factor. induces ACCP promoter activity.21l To further investigate the inhibitory 
rote of NRFI in the transcriptional regulation of ACCP promoter activity. we next 
cotransfected ACCP promoter deletion constructs ± USFI ± NRFI expression 
vectors into neonatal cardlomyocytes, CV-1 IHxoblasts and HepG2 hepatocytes. 
a) NRF1 inhibi ts USF1+C1ependent induction of ACCP promoter activity 
As previously sholMl, cotransfection with USFI further increased basal ACCP 
promoter activity for all the deletion constructs in cardiomyocytes (p<O.OI vs. 
basal ACCp promoter activity) (Figure 8A). NRF1 overe)(pression inhibi ted 
USF1-dependent induction of ACCP promoter activity In all cell lines tested 
(p<O.05 vs. pPIIP-1317{+65, pPUP-569/+65. pPllp-93f+65, pPIlj3-18/+65). 
However. the inhibitory eHect of NRFI overe)(pression In cardiomyocytes was 
abolished with the pPIIP-38/+65 deletion construct, possibly due to severe loss of 
USfl responsiveness as indicated before (chapter 2, Figure BA). We have 
previously reported that NRFI or USFI overe)(presSion induces basal ACCj3 
promoter activity in non-cardiac derived cell lines. We therefore reasoned that 
simultaneous cotransfection of NRFI and USFI would further induce USF1-
mediated ACCP promoter actrVlty. Unexpectedly. NRF1 overe)(pression markedly 
attenuated USF1-induced ACCP promoter activity for several deletion construc ts 
(p<O.05 ... s. pPllp-13171+65, pPIlj3-569/+65, pPIlj3-931+65, pPIlj3-38/+65) except 
,{).> 
for the pPI I ~-181+65 construct in CV-1 fibroblasts and the pPII~-38/+65 conslruc t 
In HepG2 hepatocytes (Figures 88 and C) These d,lIa therefore strongfy 
suggest an Interaction between NRFI and USF 1 in regulating ACC~ promoter 
actJVily in these ceH Imes. 
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Figure 8: NRFI overcxpression inhibits USF1 -dependenl induction of ACCP 
promote r activi ty. 
(A) Neonatal cardiornyocyres (B) CV-l fibroblasts and (e) HepG2 hepatocytes were 
transiently cotransfeCled WIth ACCP promoter de~tion constructs and a USF1 
expression v!!(;\or (black bars) ACCP promoter deletion constructs were afso 
simultaneously cotransfeded WI'h USFI and NRFI expression vectors (gray bars) for 24 
hours and looferase activit ies measured ResulTS are expressed as relatIve Il.lCiferase 
UOils normalized to the actiVity of vector only (pGL3-Baslc '" 1) These data are 
represented as mean .t SEM of 2 or more independent expenmenls perlormed In 
tnpllcates. ·p<O.05 vs ACC~ + USFI 
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3.3.4 NRFl overel(pression inhibits endogenous USFl transcriptional 
activity 
We have previously demonstrated that the endogenous transcriphooal actiVIty of 
the USFI reporter coostruct was significantly higher compared to control reporter 
construct In neonatal ccrdlomyocyles and CV-l fibroblasts (chapter 2, Figure 8). 
To assess whether endogenous USFI trWlscriptlonai activity is under the cootrol 
of NRFI. we ootransfected a USFI reporter vector ± an NRFI expression vector 
Into neonatal cardlomyocytes, H9C2 myoblasts and CV-l fibroblasts In 
agreement with our USF t overe.xpressloo studies, endogenous USFI 
transcriptional activity was signtficanUy higher than the control vectOf' in all cell 
lines (p<O.OOl vs. USF1-luc). rAoreover. cotranslectlon with NRFI significantly 
diminished endogenous USFI transcriptional activity in all cell lines tested 
(p<O.OOI 'IS pUSF1-luc + NRF1) (Figures 9A. 9B and 9C). 
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Figure 9: NRF1 ovcrexpresslon Inhibits endogenous USF1 transcriptional 
activity. 
(AI Neonatal card>omyocyl~. tB) H9C2 myoblasts and (C) CV-l fibroblasts were 
tr3nSlenlly cotransfected with a pUSF1-l uc reporter ~eclor ± an NRFI expression vector 
for 24 hoUT'S and luaferase acbVllies measured. Rl!SIJlts are expressed as relauve 
luclferase unots normahzed to the ilcllvlty 01 vector only (pComrol-Luc " 1). These data 
ale represented as mean :i SEM of 2 or more indepe!1denl 8Kperiments performed in 
triplicates °p<O 05 vs pConuol-Lue; #p<O 05 V!i pUSF1-Luc 
1U8 
3.4. Discussion 
3.4.1. ROLE OF PPARu IN TRANSCRIPTIONAL REGULATION OF ACCP 
a) In vivo fatty acid utilization mouse model 
Previous invesllgators have shown that physiological and pathophysiological 
conditions that promote FAO inhibit ACCP protein expression thereby relieving 
CPT1 inhibition?lS, 2:J!I Since malonyl·CoA (ACCP product) inhibits CPT1 under 
conditions favoring glucose metabolisrn,2!;7 1lnvestigaled the molecular regulation 
of ACCp under FAQ·induclng conditions 
To achieve this, I set out 10 establish an in vivo I-A utilization mouse model by 
activation of PPARu, a well·known FA responsive transcription factor. PPARu is 
activated by several endogenous and synthetic ligands (e.g. long·chain fatty 
acids and fibrates).140 In this study, I administered olive oil, a natural source of 
oleic acid241 ± Wy·14,643, a speci fic PPARu aclivatorH 10 mice for three 
consecutive days. I observed a moderate reduc1ion in systemic FFA levels with 
olive treatment, reaching stallsticat significance with a combination of olive 011 
and Wy·14643 treatment. Since Wy·14,643 Is a hypollpldemic drug, these results 
are not unexpected. Similar lipid·loweling effects were observed in obese mice2•3 
and lipoatrophy·jnduced diabetes...... However, systemic glucose levels were 
unchanged by either olive oil alone or in combina~on with Wy·14643 (data not 
shown). I also found thai administration of olive 011 alone or in comblna~on Wy-
14,643 increased MeAD gene expression, an indication of increased FA p. 
oxidation in the heart. These data are In agreement with Van der Lee et al.101 
IW 
who also found that that administration of FAs (oleic and palmitic acids) or Wy-
14.643 induced expression of several FA utilization genes in vitro. These data 
Iherefore support the establishment of an in vivo FA ulilization mouse model. 
However. a limitation of this part of the stUdy is that we did not measure ex vivo 
cardiac fuel substrate oxidation rates for the various treatment groups. At the 
time. the method was not established In our laboratory (due to lack of apparatus 
and costs), However. the labor.ltory is currently In the process of acquiring the 
necessary equipment to establish Ihese methods for the mouse heart. 
b) PPARa -mediated metabolic changes regulate ACCIl gene expression 
To further Investigate the regulation of ACCIl gene expressIOn. J next measured 
Iranscnpt levels of ACCIl in the mouse heart. Here, PPARa. activation by olive oil 
resulted in a non-significant induction of ACCj3 gene expression. Moreover. a 
combination of olive oil logether with Wy·14,643 resulted in a significant Increase 
of ACCj3 gene expression. These findings were rather unexpected since 
PPARo-driven FAO condilions such as exercise, fasting and high fat feeding 
have beeo shown to downregulate ACCj3 protein expression.:rn, 239. 263 Also, 
others have demonstrated Ihal accumulation of Intracellular long-chain FAs 
inhibit ACCj3 gene expression in the pancreatic beta cells.-
In this study. Wy-14,643 and olive ()I administratioo lead to Significant reduction 
in systemic FFA levels In mice. Here, I speculate that, the observed upregulation 
of ACCj3 gene e~pression following treatment with olive oil and Wy-14,643 may 
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be a consequence of reduced circulating FFA levels. I propose that with 
abundant supply of FFAs. aCCtJmulallOn of intracellular long-chain FAs may 
inhibit ACCP gene transcription. thereby promoting FAO through a) CPT1 
activation and b) ligand-induced PPARa aclivatiOfl.m However. if FAO is 
continuously stimulated through PPAR,~ activation. this may lead to reduced 
Circulating FFA levels thereby relieving the long-chain FA inhibition on ACCp. 
Such a negative regulatory effect could be beneficia!, especially under FFA-
limiting conditiOns e.g. prolonged fasting or chronic activation of PPARu. 
Although a direct effect of PPARu cannot be excluded. FFA clearance may 
therefore be responsible for the induction of ACCP gene expression obselVoo 
with olive oil and Wy-14643 admlnlstralion. In agreement. others have reasoned 
that PPARu-independent transcriptional regulatiOn of non-PPARu target genes 
may be due to cellular metabolic changes induced by adminislration of PPARn 
agonists such as Wy-14.643,ZIl. so For example. decreased cardiac GLUT4 gene 
tlxPJ~:;iuli Ii",:; l.>t:!I:!U vl;",,,"vt!d rulluwillY Wy-14 .643 ht!alillt:lllt. '" Alw, P"'!1i:lljiOj 
el.al.271 consistently demonstrated decreased cardiac GLUT4 protein levels In 
three different models of elevated circulating FFAs I.e. diabetes. high fat feeding 
and fasting. Furthermore. FFA clearance induced by Wy-14.643 has also been 
associated with improved insulin stimulated glucose uptake,'.J· .45,.<6 
Increased ACCI3 expression Is also associated with elevated glucose levels·7l 
and should therefore resull in increased malonyl-CoA levels and inhibition of 
FAO, This lnterptey between glucose and FA availability may be implicated in the 
"' 
mechanism of ceUular adaptation to variOus stimuli as proposed by Young et 
aI.SI With the dynamIC nature of fuel substrate supply to the heart. it is possible 
that fuel substrates (actmg as signaling intermediates) relay the message of 
decreased FFA supply 10 the ceWs transcriptional machinery which in tum 
increases malonyl-CoA levels by upregulating ACCIJ. In this manner, it is 
posSIble that the celt may allicipate" the reduced FFA supply and prepares in 
advance by increasing ACC~ gene transcnptioo and thereby decreasing FAO 
rales. Here. glucose-sensing transcnptJonal modulators may play a tOle to 
elevate ACC~ gene transcription. In summary. these data suggest thai PPARo:· 
mediated metabolic changes such as reduced systemic FFA and suslalned 
glucose levels may be responsible for upregulalion of ACCIJ gene expression 
observed. However. further slud,es are required to Iully dellfloote the precise 
molecular mechamsms that underpn these Interesting findings 
c) PPARu does not directly activate ACCp promotor activIty In cardiac-
derived cells 
To gain further insight Into the regulation of ACCIJ gene transcription by PPARu. 
I cOlransfected a PPARo. expression veclor together With the full-length ACCIJ 
promoter construct Inlo cardiomyocytes and H9C2 myobiasts. PPAR(( 
overexpression did not significantly aiter ACCIJ promoter activity in neonatal 
cardiOmyocytes or H9C2 myoblasts These data confirm my earlier proposals for 
the mouse In vivo data I.e. that Ihe upregulation observed with Wy-14,643 and 
olIVe 011 administration Is not due to direct activation of PPARrt 
III 
Conversely, PPAR" overexpression significantly induced ACC~ promoter activity 
in the 'cardiac null-background' CV-l fibroblasts. It is well documented that 
PPARu heterooimerizes with Its obligate partner. RXRfl, binding to peroxisome 
proliferator response elements (PPRE) on prcmoters of target genes?4r. 2~! For 
example. it was previously shown that overexpression of RXRu further activated 
musde regulating factor 4 (MRF-4)-induced ACC~ promoter activity 111 NIH3T3 
fibroolasts .'·o7 Here, R.XRu alone dkl not have ilny effect on basal ACC~ 
promoter aclivity2ll7 whereils I have demons/rilted that PPARu illone induce 
ACC~ promoter activity in CV-l cells. These discrepancies necessitate fu rther 
investigations in order to eluddate !he role of PPARaJRXRu interaction (n the 
regulalion of ACCP gene expression. 
In summary. the I1rst part of this chapler shows that ACC~ gene regulation is 
controlled at multiple levels in the mouse heart, underscoring the complexity of 
mdecular regulatory mechanisms. We propose that systemic PPARu activation 
does not directly inl1uence ACC~ gene expression In the heart. However. we 
suggest that Its secondary effects on FFA clearance and Improved Insulln-
stimulated glucose uptake may be responsible for the induction of ACCIl 
transcript levels. Intriguingly, as yet unidentified transcriptional mechanisms 
directing molecular regulation of ACCIl in non·cardiac Ussues merits further 
Investigation. 
III 
d) Limitations and future directions 
Olive oil is a natural source of oleic add. Oleic acid Is an endogenous ligand of 
PPARo, therefore olIVe oil adrmnistraIJon to mice was chosen as model of 
endogenous PPARo actlvallOO in VIVO. On the other hand. the synthetic PPARo 
ligand. Wy-14.643 has been extensively used as a speofic ac11vator of PPARo 
In our laboratory, another study investigating lhe effect of PPARa activation by 
Wy-14,643 administration alone found that it did not slgruflcantly alter rat cardiac 
ACCI3 gene Iransaiption compared to controls (dala not stlCMlrl), However. in 
this study, we were limlled due 10 the prohibitIVe costs of the Wy-14,643 
compound. In lighl of thiS. we \/lough! IhallOO best way to activate PPARo and 
cardiac FAO would be 10 employ Wy-14,643 togelher with a natural ligand. 
However, future experiments WIll be conducted in orde..- to dearly show whether 
Wy-1 4,643 alone affecls mouse ACCI3 gene expJ9SsJOn The follOWing 
experiments will be considered: administration of oleic acid, oleic acid with Wy-
14,643 and Wy-14,643 alone to a) mICe and b) cardiomyocytes, H9C2 
myoblasts, CV-1 fibroblasts and HepG2 cells. Subsequently. I will measure: 1) 
ACCI3 gene transcript levels using reat-time quantJtative RT-PCR, 2) ACCI3 
promoler acllvlty using reporter assays and 3) ONA:protelO binding aclivlty using 
the electrophoretic mobilily shift assay (EMSA) and chromatin 
immunopreapltatlOll (ChiP) assays. 
The role of FA-responSive lranscnptional factors, PPARu and RXR« In the 
regulation of ACCI3 gene transcription deselVes further lnvestlgallon. In thiS 
'14 
regard, the follOWIng experiments will be coosldered I,e, ootransfechon of RXRtl 
expression vector alone and cotransfectiOn of RXRrJPPARu expression vectors 
together With tho ACCP promoter In both cardiac and non-card,ac cell tmes. 
Neither PPARll nor RXR(~ expression vector alOfie had an effect 00 basal ACCIJ 
promoter activi ty. therefore I will investigate whether PPARft and RXR,~ can 
affect USF I·induced ACCP promoter activity. 
11 !' 
3.4.2. THE ROLE OF NRF1 IN TRANSCRIPTIONAL REGULATION OF ACCP 
An important aspect of the transcnptlonal conlrd 01 nlllochondrial biogenesis is 
mediated by Ule master regulator PGC 10 that Induces target genes logether wIth 
coact lvators such as NRF1 and PPARo.D5 !II; 2'9. 2SO NRF1 Induces several 
nuclear-encoded 111Iiocilondriai respira tOl)' enzymes.eo while PPARo regulates 
Ihe e~press!on 01 numerous FA uhlizal!Qn genes lor eg CPT! and MCAD 
Furthermore. e~ercise-medlated sllmulatlCMl 01 FAO Is beheved 10 be 
transcript ionally driven by NRFI and PPARo ". III Whether these transcnpt!Ofl 
fadors promote FAO. in part. by represslIlg Ihe inh!Mory mechamsm that 
controts long-chain FA (LCFA) ImportatlOl1 into Ille ffiltochondfla Is largely 
unknown Here ACCp regulates m,tochondnal transler 01 LCFAs vIa productIon 
01 malonyl-CoA. a polent inhibitor of CPT!. thereby leading to a reduclJOfl III 
FAO Of note. e~erclse-meOlated sllmulaUon of FAO IS assoaaled with elevated 
levels of NRF1 and PPARo aocompanlOO by the IIlcreased eXjlf"9SSlon of FA 
enzyme-enco(1ing genes such as AMPK and CPT! /I In thiS study. we explored 
the role of NRF1 In reg\Jaung ACCIJ gene regulation In the heart To our 
knowledge. thiS IS Ihe first study \0 IIl1phcate NRF1 as a novel inhibitor of ACCP 
promoter activity. 
We found that NRF I oV9(expresslOl1 markedly al1enualed ACCI} promoter 
activlly In neonatal cardiOm~es and cardiac-derived H9C2 myOblasts 
Elevated NRFI gene expression was previously shown \0 be associated WIth 
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upregulation of CPT1 gene e~pression in neonatal card imyocytes.e9. W 
Moreover, prevIOus studies have shown that the expression of NRF1 1l6 and epn 
25 1 is upregutaled In response 10 exercise. It has also been establ ished Ihal 
exercise induces FAD by aclivatlon of AMPK which in tum phosphol)1ates and 
inhibits ACe enzyme activity. '99, 2r.2 :153 Hence, AMPK has been recognized as a 
key regulator of FAD. Whether AMPK. in addition to phosphol)1ation of ACCP, 
also inhiblls tranSCriptional regulation of ACC!) is still unclear. A recent study 
reported that administration of p-guanadinoproplonlc acid (!)-GPA). an AMPK 
activator, was associated with increased NRF1 promoter binding activity.g, These 
findmgs therefore provide a possible transcr ipt ional mechanism through which 
AMPK could inhibit ACCP gene expression In the hean However. two studies 
argue against this concept. In tile first Instance. NRFI overexpresslng mice did 
not show significant changes in basal palmitate o~idation !iti We propose that 
since these mice were not challenged with various stimuli Ihat Induce FAD, the 
role of NRFI as a positive regulator of FAO cannot be excluded Secondly, Nau 
et al 62 reported that fetal hearts e~h i bited elevated NRFI levels associated with 
reduced cpn gene expression. We argue that th is discrepancy may be due to 
the reduced ability ulll1e lelu:; lu ulili<:e FA:; ",,,d "ul "l.-,,-,"':;:;arily dIll< lu r"dlK.;",LI 
uprogulalion of CPT1 gene e~presslon by NRF1 . 
To investigate whether the inhibitory effect of NRFI overexpresslon on ACCP IS 
cardiac-specific, we repeated experiments employing non-cardlac cell lines I.e. 
eV-\ tibroblasls and HepG2 hepalocytes. Surprisingly. we found thai NRF1 
II J 
overexpression IndUCed ACCI3 promoter actlVI!y in both CV-l fibroblasts and 
HepG2 hepatocytes However, the NRF1-lnduced ACCP promOler activity was 
srgnrfrcanlly hrgher compared to the USF1-medlated Increase In ACCP promoter 
activity III Irght of these findings. we furthe l tested whether cotranslectron of 
NRrl and USFI would inhibit or lurtl1er indUCe USF1-rnedlated induction of 
ACCI3 promoter activity We found th<lt USF1 -mediated Induction of ACCP 
promoter activ ity was markedly attenu;Jted In both cell hnes !nrogUlngly, NRF1· 
mediated induction 01 ACCI3 promoter activity was maintained while the USF1-
mediated induction 01 ACCP promoter acllYity was abolished ThiS was rather 
unexpected since NRF 1 differentially regulated basal ACCP promoter achvlty 
Nonetheless, lI1ese data cle<lr1y IIl(lIcate thaI NRFI may Interfere With USfl 
bind ing to the ACCj3 promoter To further explore the Inhibitory effect of NRFI 
on USF1-moomted ACCI3 p<<)I1101er adlvlty we trans/ected cells With a USFI 
translucent reporter vector and a NRFI expressiOn vector AUenualron of 
endogenous USFI tranSCriptional acllYity wllh NRFI cotmnsfectloo confirmed 
thaI NRFI interferes With USF '-mediated induction of ACCI3 promoter activity 
Overall. these data point to a novel role fOI NRF 1 In regulating ACCj3 eXpreSSion 
In the heart and raises the poSSIbility thaI NRFI may COOfdinately regulate genes 
Involved In mitochondrial fA uptake 
As far as we could aSCertain, there are no classic NRFI binding elements 
1(TIC)GCGCA(CIT)GCGC(AiG)] located With in the human ACCI3 gene promoter. 
However, II has been suggested that certain transcriplionai coactlvators do nOI 
! 1 S 
bind directly to promoter sequerce elements but rather interact with multiple 
co/actors to activate or repress gene transcripboo.eo. N. ZlS, 2)5 In agreement with 
this concept. NRF1 increased gene expression of GLUT4 and muscle-specific 
COXVlaH and COXVlll desplle a lack of NRfl promoter bmding elements.- Zl5. 
2.JII Instead. the NRF1-medlaled effects are dependent OIl MEF-2 and/or E-oox 
consensus elements for ther expression. 
The human ACCf:I promoter contains several E-boxes. In light of this. we 
employed ACCI3 promoter deletion constructs 10 investigate whether NRFI can 
Interact with USFI (E-box binding protem). to regulate ACCjl promoter actJlflty. 
Since ACCj3 promOler activity was similar when transfectlng with the pPIIj3-
5691~65 or pPIlI3-931+65 deletion constructs, the Inhibitory effect of NRFI was 
not mediated via a cluster of three E-boxe5 (E-boxl-3) located between -569 and 
-349. Similarly. m chapter 2. we reponed that E-boxes{I-3) were not involved in 
USF1-medlated Induction of ACCI3 promoter actiVity However, the USF1-
mediated increase of pPlljl-l8/+65 promoter actiVIty (containing E-box4 only) 
was mar1l.edly attenuated by NRfl OllerexpresSiOn In cardiornyocytes However, 
this indudion of ACCj3 promoter activity was maintamed or moderately inhibi ted 
by NRFI In CV·l fibroblasts and HepG2 hepatocytes. resped:ively. These data 
Indicale that NRFI may be interfering with USFI binding to E-box4 in 
cardlomyocytes. However. in CV-l fibroblasts and HepG2 hepatocytes. NRFI 
probably increases ACCIl promoier ad:ivity via E-box4. Notably. USF1-mediated 
Induction of pPlljl-l81+65 promoter actIVity (conlainlflQ E-box4 only) was reduced 
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blot assays to con firm my in vitro work: (trans/eclion assays), However, our 
laboratory IS currently considering the purchasmg a thermal cycler In order to 









Figure 11 : Proposed mo lecular mechanism for NRF1 in the transcriptional 
inhibition of ACCIl and regulation of fatty acid o)( idation 
Chapter 4 
Conclusion 
reduced fatty acid oxidation obseIVed in type 2 dIabetic patients may be 
a!!nbLfed to Increased ACCI) gone expression and !he subsequent accumulation 
of malonyl-CoA levels. 11I 2Jl,3 These data raise the Intefestlng possibility that 
USFI levels could be Increased within the diabetic context resulting in tho 
Induction of ACCI) gene expression, increased malonyl-CoA levels and 
decreased CPT1 activity However, further studies are required to investigate 
this jXoposal and the contribution of this pa!hway 10 the accumulation of 
damaging inlracellular lCFAs in lhe heart. 
In lighl of this, the Idonllflcatlon of novel inhibitors regulatmg ACCI) expressiOl1 
may provide a mechanism through which detnmental intracellular lipid 
accumulation and Insulin resistance may be controlled. In support of this 
concept. ablation of the ACCI) gene was accompamed by enhanced in vivo falty 
acid oxidation ra tes and strong resistance of these transgenic mice to diabetes 
and obeSity when challenged with a hlgtI-fat/hlgtKarbohydrate diet.'''' We 
lherefore Investigated reglJatory mechanisms thai may repress ACCI) gene 
transc~tion. We hypothesized that transcription mooulat()(s controlling genes 
PromOll1'lg enelgy prodUCing pathways also Inhibit ACCI) transcription In order to 
promote fatly acid oxidation. Here. for the first lime as far as we are aware, we 
ldenUfied NRFI as a novel repressor of the ACCI) gene promoter In the heart and 
In non-cardiac tissues. Furthermore. we report thaI NRFI Inhibits basal and 
USF1-lnduced human ACCI) promoter activity. Also_ endogenous USFI 
transcriptional activity was mar1tedly atlenualed by NRFI overexpresslOn. Our 
12(, 
findings provide further mSlght regardmg NRF1-media!ed repression of ACCP 
gene transcripllOn. Since we haYe suggested lila! USF1-mediated induction of 
ACCp promoter actlY~y may haye deleterious effects due to accumulation of 
LCFAs, we propose that the newly identifi!!d NRF1-mediated repression of ACCp 
transcription may In fact promote LCFA clearance. In this regard, exercise 
improves Insulin resistance yia LCFA clearance. Moreover, the beneficial effects 
of exercise have been extensiYely docurrented as a therapeutic intervention for 
diabetes. insulin resistance. ooronary haar! disease, hypertension and other 
metabolic disorders Exercise also inhibits ACCp gene expression thereby 
increasing fatty aCid OXidation .23/! We therefore propose that NRF1-driven 
transcriptional inhibition of ACC~ may be a potential mechanism through which 
exercise exerts its beneficial effects. 
Conversely, some Investigators have reported the use of pharmacological 
inhibitors of tally add oxidation as a potential treatment for heart failure. " o In 
support. mice lackmg PPARo. a fany acid-responsive transcrlpHonal regulator. 
were protected agamst diabetes-induced cardiac hypert rophy,129 whereas 
PPARa overexpressmg mice displayed a diabetes-like metabolic phenorype.20 
Furthermore, reactivation of PPARo ·juring the development of cardiac 
hypertrophy exacerbated cardiac function. 102 Therefore. despite the potential 
cardioprotective effects of ACCP inhibition. it appears that under certain 
conditions Its activation may Indeed be beneficial. In this context, our 
identification of both positive and negah\l€ regulators of ACCP gene transcription 
'" 
may resultl!l the development of novet therapeutIC agents tha t wilt help alleviate 
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